[go: up one dir, main page]

US20050187191A1 - Methods and compositions for the treatment of respiratory syncytial virus - Google Patents

Methods and compositions for the treatment of respiratory syncytial virus Download PDF

Info

Publication number
US20050187191A1
US20050187191A1 US10/781,894 US78189404A US2005187191A1 US 20050187191 A1 US20050187191 A1 US 20050187191A1 US 78189404 A US78189404 A US 78189404A US 2005187191 A1 US2005187191 A1 US 2005187191A1
Authority
US
United States
Prior art keywords
alkyl
alkenyl
rsv
alkynyl
straight chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/781,894
Inventor
Louis Kucera
Susan Morris-Natschke
Khalid Ishaq
Ronald Fleming
Jan Hess
Yunsheng Huang
Russ Read
Phillip Furman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Kucera Pharmaceutical Co
Wake Forest University Health Sciences
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/781,894 priority Critical patent/US20050187191A1/en
Assigned to WAKE FOREST UNIVERSITY HEALTH SCIENCES, UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE, KUCERA PHARMACEUTICAL COMPANY reassignment WAKE FOREST UNIVERSITY HEALTH SCIENCES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: READ, RUSS H., KUCERA, LOUIS S., FLEMING, RONALD A., HESS, JAN V., HUANG, YUNSHENG, ISHAQ, KHALID S., MORRIS-NATSCHKE, SUSAN L., FURMAN, PHILIP A.
Priority to PCT/US2005/003972 priority patent/WO2005099719A2/en
Publication of US20050187191A1 publication Critical patent/US20050187191A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: WAKE FOREST UNIVERSITY
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin

Definitions

  • This invention relates generally to methods and compositions for the treatment of respiratory syncytial viral infections.
  • Respiratory syncytial virus is a negative-strand RNA virus belonging to the family, Paramyxoviridae and to the genus, pneumovirus.
  • the structure and composition of RSV have been described in detail. (Domawchowske et al., Clinical Microbiology Review 12:298-309 (1999)).
  • Two major subgroups of RSV, type A and B, have been identified, as well as antigenic variants within each subgroup (Anderson;, L. J. et al., J Inf Dis 151:626-633 (1985); Mufson, M. A. et al., J Gen Virol 66:2111-2124 (1985)).
  • RSV is a major human pathogen, responsible for respiratory infection in patients of all ages. Typically, RSV infections remain localized to the upper respiratory tract, causing profuse rhinorrhea, nasal congestion, pharyngitis, cough and fever. In some patients, however, infection spreads to the lower respiratory tract. Severe lower respiratory tract disease (e.g., pneumonia, bronchiolitis) results, and typically requires hospitalization and breathing support. In some circumstances, RSV may be fatal.
  • RSV is highly contagious. Spread person to person through infected nasal and oral secretions, RSV can also live on surfaces for hours. Typically, RSV occurs in epidemics that last up to 4 months, from late fall through early spring. Children in day-care centers and preschools are at significant risk, and the elderly in hospitals and nursing homes are particularly vulnerable. School-aged children are commonly implicated in the spread of the disease, both to their younger siblings and their parents.
  • RSV accounts for 13.5-21.6% of the $2.25 billion in costs associated with hospitalization of infants with lower respiratory infections. The total costs are even greater, as these include treatment for other populations at high risk for RSV, including the elderly and the immunocompromised. RSV also affects healthy adults, and even in a milder form is associated with significant work absences. Re-infection with RSV is very common, forcing additional costs on the healthcare system. The health-related effects of initial infection in some populations, moreover, may be long term. Recent data indicates that RSV-induced lower respiratory tract infections in infants may be linked to the development of asthma or reactive airway disease in later childhood (Sigurs, N. et al., Am J Resp Crit Care Med 161:1501-1507 (2000)).
  • RSV infection Despite the prevalence of RSV infection, and significant advances in scientific understanding, there are few approved treatments and even more controversy surrounding the proper management of high-risk populations. In general, most treatments for RSV are symptomatic. Supportive therapy may include monitoring, removal of secretions, intravenous hydration, administration of oxygen. Bronchodilators (e.g., metaproterenol or albuterol) and corticosteroids may be used, but most studies have concluded that there is insufficient evidence of therapeutic benefit except, perhaps, in certain subgroups (i.e., infants). Studies on vitamin A and interferon have also yielded disappointing results. Exogenous surfactant administration may be helpful in improving oxygenation in infants with severe RSV respiratory infection (Greenough, Acta Paediatr. Suppl. 2001, 436: 11-14).
  • Ribavirin (1-beta-D-ribafuranosyl-1,2,4-traizole-3-carboxamide) is a synthetic nucleoside analog with broad spectrum antiviral activity against RSV, influenza, parainfluenza, adenovirus, measles, Lassa fever, and Hantaan viruses. Ribavirin is FDA-approved for use in very ill children hospitalized with severe RSV-related pneumonia. Yet, the use of Ribavirin even for this limited purpose is controversial in view of its mixed clinical history, cost and difficulty of administration and potential safety issues for secondary exposure.
  • the humanized murine monoclonal antibody palivizumab (Synagis®; Medlmmune, Inc.) has also been approved for the prevention of RSV lower respiratory tract disease. It is considerably easier to administer than RSV-IG (i.e., by monthly intramuscular injection) and doesn't interfere with normal vaccination, but it is also very costly.
  • inactivated virus e.g., formalin-inactivated vaccine
  • live-attenuated viruses e.g., cold-adapted and/or temperature sensitive vaccine
  • subunit vaccines e.g., RSV F subunit vaccine
  • U.S. Pat. No. 5,962,437 to Kucera et al. discloses methods of treating viral infections, in particular, HIV-1, hepatitis V virus, and herpes viruses.
  • the compounds disclosed in U.S. Pat. No. 5,962,437 are phospholipids or phospholipid derivatives substituted at the 1-position with a C 6 -C 18 alkyl group and at the 2-position with a C 6 -C 14 alkyl group.
  • the patent suggests that the compounds disclosed therein could also be used to treat RSV.
  • the successful treatment of RSV with the disclosed compounds could not have been predicted.
  • the invention is directed to compounds of Formula I: and pharmaceutically acceptable salts or prodrugs thereof,
  • Y and X are independently C 1 -C 14 alkyl, C 2 -C 14 alkenyl, or C 2 -C 14 alkynyl.
  • Y is —C 10 H 21 ; and X is —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH 2 CH 2 CH 2 CH 3 , or —C 10 H 21 .
  • Y is —C 11 H 23 and X is C 1 -C 5 alkyl
  • Y is —C 9 H 19 and X is C 9 -C 11 alkyl.
  • the compound of formula I is 3-dodecanamido-2-ethoxypropyl-1-phosphocholine, 3-decanamido-2-ethoxypropyl-1-phosphocholine, 3-decanamido-2-decyloxypropyl-1-phosphocholine, 3-dodecanamido-2-octyloxypropyl-1-phosphocholine, 3-dodecanamido-2-dodecyloxypropyl-1-phosphocholine, or 3-dodecanamido-2-butyloxy-1-phosphocholine.
  • the invention is also directed a compound of Formula II: and pharmaceutically acceptable salts or prodrugs thereof,
  • R 21 is C 9 -C 12 alkyl and R 22 is C 1 -C 12 alkyl.
  • R 21 is C 9 -C 12 alkyl and R 22 is C 1 -C 5 alkyl.
  • R 21 is C 9 -C 12 alkyl and R 22 is C 8 -C 12 alkyl.
  • the invention is also directed to a compound of Formula III: and pharmaceutically acceptable salts or prodrugs thereof,
  • R 1 is —C 11 H 23 and X is —C(H)(O—C 1 -C 5 alkyl)- or —C(H)(O—C 1 -C 5 alkenyl)-
  • R 1 is —C 9 H 19 and X is —C(H)(OC 2 H 5 )—
  • R 1 is —C 9 H 19 and X is —C(H)(OC 10 H 21 )—.
  • the invention is also directed to a compound of Formula IV: and pharmaceutically acceptable salts or prodrugs thereof,
  • R 2 is C 1 -C 5 alkyl or C 2 -C 5 alkenyl.
  • R 1 is C 8 -C 12 alkyl and R 2 is C 1 -C 12 alkyl.
  • R 1 is C 8 -C 12 alkyl and R 2 is C 1 -C 5 alkyl.
  • R 1 is C 8 -C 12 alkyl and R 2 is C 8 -C 12 alkyl
  • the invention is also directed to a compound of Formula AA-1: and pharmaceutically acceptable salts or prodrugs thereof,
  • the invention also provides a method for treating a host infected with RSV.
  • This method comprises administering to a host in need thereof an anti-RSV effective amount of compound of Formula I-IV or AA-1, or a pharmaceutically acceptable salt or prodrug thereof.
  • the host is a mammal. In one embodiment, the host is a human.
  • the compound of Formula I-IV or AA-1, or a pharmaceutically acceptable salt or prodrug thereof can be administered orally, intravenously, parentally, intradermally, subcutaneously, topically, or by inhalation.
  • the invention further provides a method of inhibiting RSV replication in a cell.
  • This method comprises administering to the cell, in an amount effective to inhibit replication of RSV in a cell, a compound of Formula I-IV or AA-1, or a pharmaceutically acceptable salt or prodrug thereof.
  • the host is a mammal. In one embodiment, the host is a human.
  • the invention also provides pharmaceutical compositions comprising a compound of Formula I-IV or AA-1, or a pharmaceutically acceptable salt or prodrug thereof.
  • the invention also provides a kit comprising a compound of Formula I-IV or AA-1, or a pharmaceutically acceptable salt or prodrug thereof.
  • the invention also provides the use of a compound of Formula I -IV or AA-1, or a pharmaceutically acceptable salt or prodrug thereof, optionally with a pharmaceutical acceptable carrier or diluent, for the manufacture of a medicament for the treatment of a host infected with RSV.
  • FIG. 1 illustrates a process that may be used generally for obtaining a 3-alkylamido-2-alkoxypropylphosphocholine.
  • the compounds useful for the treatment of RSV infection are alkylamidophosphocholine compounds or analogs thereof and pharmaceutically acceptable salts or prodrugs thereof (hereinafter “compounds of the invention”).
  • the methods involve administering an effective amount of a compound of the invention, optionally in a pharmaceutically acceptable carrier, to a host in need thereof.
  • the compounds of the invention can be used singly or in combination.
  • the methods treat or retard the progression of clinical illness in an individual infected with RSV.
  • the methods of treatment can be used to treat severe RSV lower respiratory tract infections including, but not limited to, the treatment of RSV bronchiolitis and pneumonia.
  • the invention also includes a method of inhibiting RSV replication in a cell. This method comprises administering to the cell, in an amount effective to inhibit replication of RSV in a cell, a compound of the invention.
  • Compounds of the invention that can be administered include, but are not limited to, 3-dodecanamido-2-ethoxypropyl-1-phosphocholine, 3-decanamido-2-ethoxypropyl-1-phosphocholine, 3-decanamido-2-decyloxypropyl-1-phosphocholine, 3-dodecanamido-2-octyloxypropyl-1-phosphocholine, 3-dodecanamido-2-dodecyloxypropyl-1-phosphocholine, 3-dodecanamido-2-butyloxy-1-phosphocholine, optionally in a pharmaceutically acceptable carrier.
  • the compounds may possess anti-RSV activity or be metabolized to a compound or compounds that exhibit anti-RSV activity.
  • the effectiveness of the compounds of the invention may be due to the fact that they are phosphocholine (PC) analogs which may provide a surfactant effect to assist in the removal of pulmonary secretions and improve oxygenation that is beneficial against RSV if administered by pulmonary administration.
  • PC phosphocholine
  • PC moiety is an essential component for a phospholipid to exhibit optimal antiviral activity (Piantadosi et al., 1991, J. Med. Chem. 34:1408-1414; Krugner-Higby et al., 1995, AIDS Res. & Human Retrovir. 11:705-712).
  • Lipid compounds comprising phosphatidic acid, phosphoethanolamine, phosphoalkylpyridine, alcohol or quarternary amine salt moieties were less active, more toxic, exhibited much lower differential selectivities or some combination of these, relative to the corresponding PC lipids.
  • a PC moiety is incorporated into the lipid backbone to provide compounds that exhibit optimal antiviral activity.
  • RSV infection and related conditions include, but are not limited to, one or more conditions, such as acute respiratory illness, pneumonia, bronchiolitis (inflammation of the small airways of the lungs), tracheobronchitis (croup), and ostitis media (ear infections).
  • treatment means an approach for obtaining beneficial or desired results including clinical results, such as, but not limited to, alleviation of symptoms of a disease or condition, diminishment of extent of a disease or condition, stabilization (i.e., not worsening) of a disease or condition, preventing spread of a disease or condition, preventing or reducing occurrence or recurrence of a disease or condition, delaying or slowing of a disease's or condition's progression, and reducing the incidence of a disease or condition or the symptoms of a disease or condition.
  • the present invention encompasses racemic, optically active, and stereoisomeric forms, and all mixtures of such forms of a compound of the invention.
  • Methods of preparing optically active forms of a compound are well known in the art and include, for example, resolution of a racemic mixture of the compound using recrystallization techniques, synthesis of the compound from optically active starting materials, chiral synthesis of the compound, and chromatographic separation of a racemic micture of the compound using a chiral stationary phase.
  • the present invention also encompasses polymorphic forms and mixtures thereof.
  • Determining or assessing antiviral activity may be performed using standard tests described herein or other tests know in the art.
  • alkyl means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon.
  • alkyl include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, sec-pentyl, iso-pentyl, hexyl, iso-hexyl, sec-hexyl, heptyl, sec-heptyl, iso-heptyl, octyl, iso-octyl, sec-octyl, nonyl, iso-nonyl, sec-nonyl, undecyl, iso-undecyl, sec-undecyl, dodecyl, iso-dodecyl, sec-dodecyl, tridecy
  • C 1 -C 3 alkyl means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 1 to 3 carbon atoms.
  • C 1 -C 4 alkyl means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 1 to 4 carbon atoms.
  • C 2 -C 4 alkyl means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 2 to 4 carbon atoms.
  • C 2 -C 6 alkyl means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 2 to 6 carbon atoms.
  • C 6 -C 18 alkyl means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 6 to 18 carbon atoms.
  • C 2 -C 14 alkyl means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 2 to 14 carbon atoms.
  • C 1 -C 22 alkyl means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 1 to 22 carbon atoms.
  • C 1 -C 20 alkyl means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 1 to 20 carbon atoms.
  • C 14 -C 18 alkyl means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 14 to 18 carbon atoms.
  • C 9 -C 30 alkyl means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 9 to 30 carbon atoms.
  • alkenyl means a straight chain or branched, acyclic or cyclic, hydrocarbon having at least 2 carbon atoms and including at least one carbon-carbon double bond.
  • alkenyl include, but are not limited to, vinyl, allyl, 1-butenyl, 2-butenyl, isobutenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-1-butenyl, 2,3-dimethyl-2-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 2-decenyl, and 3-decenyl moieties.
  • C 2 -C 22 alkenyl means a straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 2 to 22 carbon atoms and including at least one carbon-carbon double bond.
  • C 2 -C 20 alkenyl means a straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 2 to 20 carbon atoms and including at least one carbon-carbon double bond.
  • C 6 -C 18 alkenyl means a straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 6 to 18 carbon atoms and including at least one carbon-carbon double bond.
  • C 2 -C 14 alkenyl means a straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 2 to 14 carbon atoms and including at least one carbon-carbon double bond.
  • C 9 -C 30 alkenyl means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 9 to 30 carbon atoms and including at least one carbon-carbon double bond.
  • alkynyl means a straight chain or branched, acyclic hydrocarbon having at least 2 carbon atoms and including at least one carbon-carbon triple bond.
  • alkynyl include, but are not limited to, acetylenyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1-butynyl, 4-pentynyl, 1-hexynyl, 2-hecynyl, 5-hexynyl, 1-heptynyl, 2-heptynyl, 6-heptynyl, 1-octynyl, 2-octynyl, 7-octynyl, 1-nonynyl, 2-nonynyl, 8-nonynyl, 1-decynyl, 2-decynyl, and 9-decy
  • C 2 -C 22 alkynyl means a straight chain or branched, acyclic primary, secondary, or tertiary hydrocarbon having from 2 to 22 carbon atoms and including at least one carbon-carbon triple bond.
  • C 2 -C 20 alkynyl means a straight chain or branched, acyclic primary, secondary, or tertiary hydrocarbon having from 2 to 20 carbon atoms and including at least one carbon-carbon triple bond.
  • C 6 -C 18 alkynyl means a straight chain or branched, acyclic primary, secondary, or tertiary hydrocarbon having from 6 to 18 carbon atoms and including at least one carbon-carbon triple bond.
  • C 2 -C 14 alkynyl means a straight chain or branched, acyclic primary, secondary, or tertiary hydrocarbon having from 2 to 14 carbon atoms and including at least one carbon-carbon triple bond.
  • C 9 -C 30 alkynyl means a saturated straight chain or branched, acyclic, primary, secondary, or tertiary hydrocarbon having from 9 to 30 carbon atoms and at least on carbon-carbon triple bond.
  • aryl means phenyl, biphenyl, or napthyl, optionally substituted with one or more of halo, alkyl, alkenyl, alkynyl, —OH, —NH 2 , —NHR 1 , —NR 1 R 1 , —NH(aryl), —NH(aryl)(aryl), —O-alkyl, —O-alkenyl, —O-alkynyl, —O-aryl, nitro, cyano, —S-alkyl, —S-alkenyl, —S-alkynyl, —S-aryl, —NR 1 C(O)R 1 , —COOH, —SO 3 H, —COOR 1 , —OP(O)(OR 1 ) 2 , —OP(O)(R 1 )(OR 1 ), —OP(O)(R 1 ) 2 , either un
  • halo or “halogen” as used herein means —Cl, —Br, —I, and —F.
  • amino means —NH 2 .
  • oxo means a methylene group wherein the two hydrogens of the methylene are replaced with double bond to oxygen.
  • heterocyclic ring means a 3 to 10 membered monocyclic or bicyclic ring which is either saturated, unsaturated non-aromatic, or aromatic containing from 1 to 4 heteroatoms independently selected from nitrogen, which can be quaternized; oxygen; and sulfur, including sulfoxide and sulfone.
  • the heterocycle ring can be attached by a nitrogen, sulfur, or carbon atom.
  • heterocycles include, but are not limited to, pyridyl, furyl, thiophenyl, pyrrolyl, oxazolyl, imidazolyl, thiazolyl, thiadiazolyl, isooxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperizinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, quinolinyl, isoquinolinyl, chromonyl,
  • heterocyclic means an aromatic heterocycle ring having between 5 and 10 ring atoms, including both monocyclic and bicyclic ring systems, wherein at least one carbon atom of one or both of the rings is replaced with a heteroatom independently selected from nitrogen, oxygen, and sulfur.
  • heteroaromatics include, but are not limited to, pyridyl, furyl, benzofutanyl, thiophenyl, benzothiophenyl, quinolynyl, pyrrolyl, indolyl, oxazolyl, benzooxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiadiazolyl, triazinyl, cinnolinyl, phthalazinyl, and quinazolinyl.
  • cycloalkane ring or “cycloalkyl,” unless otherwise specified, means a 3 to 14 membered monocyclic, bicyclic, or tricyclic hydrocarbon ring which is either saturated or unsaturated non-aromatic.
  • Representative cycloalkane rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, indanyl, 1,2,3,4-tetrahydronaphthyl, perhydronaphthyl, 1,2,3,4-tetrahydroanthracenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cycloheptenyl, cyclohetadienyl, and cycloheptatrienyl.
  • C 3 -C 8 cycloalkyl or “C 3 -C 8 cycloalkane ring” means a 3 to 8 membered monocyclic hydrocarbon ring a which is either saturated or unsaturated non-aromatic.
  • Representative C 3 -C 8 cycloalkane rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • prodrug means a compound that, when administered to an animal, is converted under physiological conditions to a compound of the invention.
  • anti RSV effective amount means and amount effective for treating RSV.
  • the term “host”, as used herein, refers to a unicellular or multicellular organism in which the virus can replicate, including cell lines and animals, and preferably a human. Alternatively, the host can be carrying a part of the viral genome, whose replication or function can be altered by the compounds of the invention.
  • the term host refers to infected cells, cells transfected with all or part of the RSV genome, and animals, in particular, primates (including chimpanzees) and humans. In most methods of the invention, the host is a human patient.
  • Veterinary applications in certain indications, however, are clearly encompassed by the present invention, such as in chimpanzees.
  • salts refers to a salt that retains the desired biological activity of the parent compound and preferably does not impart undesired toxicological effects thereto.
  • examples of salts include, but are not limited to, (a) salts formed with cations such as sodium, potassium, NH 4 + , magnesium, and calcium polyamines such as spermine and spermidine; (b) acid addition salts formed with inorganic acids including, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, and nitric acid; (c) salts formed with organic acids including, but not limited to, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid
  • a variety of compounds may be used in the methods disclosed herein for the treatment of RSV. These compounds exhibit anti-RSV activity.
  • the compounds used in the methods of the invention include compounds of Formula I: and pharmaceutically acceptable salts or prodrugs thereof
  • Y is C 1 -C 22 alkyl.
  • Y is C 2 -C 22 alkenyl.
  • Y is C 2 -C 22 alkynyl.
  • X is C 1 -C 22 alkyl.
  • X is C 2 -C 22 alkenyl.
  • X is C 2 -C 22 alkynyl.
  • X is a C 1 -C 5 alkyl.
  • X is C 2 -C 5 alkenyl.
  • X is C 2 -C 5 alkynyl.
  • X is —C 2 H 5 or —C 10 H 21 .
  • X is —C 2 H 5 .
  • Y is —C 9 H 19 or —C 11 H 23 .
  • Y is —C 11 H 23
  • X is —C 2 H 5
  • R 3 is phosphocholine.
  • Y is —C 9 H 19
  • X is —C 2 H 5
  • R 3 is phosphocholine.
  • Y is —C 9 H 19
  • X is —C 10 H 21
  • R 3 is phosphocholine.
  • the compounds used in the methods of the invention also include compounds of Formula II: and pharmaceutically acceptable salts or prodrugs thereof,
  • M is —CH 2 CH 2 —.
  • M is —CH 2 CH 2 CH 2 —.
  • M is —CH 2 CH 2 CH 2 CH 2 —.
  • M is —CH 2 CH(CH 3 )—
  • M is —CH(CH 3 )CH 2 —.
  • M is —CH(CH 3 )CH 2 CH 2 —.
  • M is —CH 2 CH(CH 3 )CH 2 —.
  • M is —CH 2 CH 2 CH(CH 3 )—.
  • M is —C(CH 3 ) 2 —.
  • M is —CH 2 C(CH 3 ) 2 —.
  • M is —C(CH 3 ) 2 CH 2 —.
  • X 1 is —S—.
  • X 1 is —O—.
  • X 1 is —NH—.
  • X 1 is —NHC(O)—.
  • R 21 is a C 1 -C 20 straight chain alkyl.
  • R 21 is a straight chain C 2 -C 20 alkylene containing not more than four double bonds.
  • R 21 is aryl
  • R 22 is a C 1 -C 20 straight chain alkyl.
  • R 22 is a C 2 -C 20 straight chain alkylene containing not more than four double bonds.
  • R 22 is a C 1 -C 5 straight chain alkylene containing not more than four double bonds.
  • R 22 is a C 1 -C 5 straight chain alkyl.
  • R 22 is hydrogen
  • R 22 is methyl
  • R 22 is ethyl
  • R 23 , R 24 , and R 25 are methyl.
  • M is —CH 2 CH 2 —
  • the compounds used in the methods of the invention also include compounds, of Formula III: and pharmaceutically acceptable salts or prodrugs thereof,
  • Y is —S—.
  • Y is —O—.
  • Y is —NH—.
  • Y is —N(CH 3 )—.
  • Y is —NHC(O)—.
  • Y is —N(CH 3 )C(O)—.
  • R 1 is C 1 -C 18 alkyl.
  • R 1 is C 2 -C 18 alkenyl.
  • R 1 is C 2 -C 18 alkynyl.
  • R 1 is C 14 -C 18 alkyl.
  • R 1 is C 14 -C 18 alkenyl.
  • R 1 is C 14 -C 18 alkynyl.
  • R 1 is aryl
  • X is a covalent bond.
  • X is a methylene that is optionally substituted with a hydroxyl, C 1 -C 20 alkyl, —O—(C 1 -C 20 alkyl), —S—(C 1 -C 20 alkyl), —C(O)N(C 1 -C 20 alkyl), C 2 -C 20 alkenyl, —O—(C 2 -C 20 alkenyl), —S—(C 2 -C 20 alkenyl), —C(O)N(C 2 -C 20 alkenyl), C 2 -C 20 alkynyl, —O—(C 2 -C 20 alkynyl), —S—(C 2 -C 20 alkynyl), or —C(O)N(C 2 -C 20 alkynyl).
  • X is a methylene that is optionally substituted with a hydroxyl, C 1 -C 5 alkyl, —O—(C 1 -C 5 alkyl), —S—(C 1 -C 5 alkyl), —C(O)N(C 1 -C 5 alkyl), C 2 -C 5 alkenyl, —O—(C 2 -C 5 alkenyl), —S—(C 2 -C 5 alkenyl), —C(O)N(C 2 -C 5 alkenyl), C 2 -C 5 alkynyl, —O—(C 2 -C 5 alkynyl), —S—(C 2 -C 5 alkynyl), or —C(O)N(C 2 -C 5 alkynyl).
  • R 2 , R 3 , and R 4 are methyl.
  • J is —CH 2 CH 2 —.
  • the compounds used in the methods of the invention also include compounds of Fonmula IV: and pharmaceutically acceptable salts or prodrugs thereof,
  • X is s-NHC(O)—, —N(CH 3 )C(O)—, —C(O)NH—, —C(O)N(CH 3 )—, —S—, —S(O)—, —(SO 2 )—, —O—, —NH—, or —N(CH 3 )—;
  • R 1 is a C 6 -C 18 alkyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • R 1 is a C 6 to C 18 alkenyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • R 1 is a C 6 -C 18 alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • R 1 is aryl
  • X is —NHC(O)—.
  • X is —N(CH 3 )C(O)—.
  • X is —C(O)NH—.
  • X is —C(O)N(CH 3 )—.
  • X is —S—.
  • X is —S(O)—.
  • X is —(SO 2 )—.
  • X is —O—.
  • X is —NH—.
  • X is —N(CH 3 )—.
  • R 2 is a C 1 -C 14 alkyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • R 2 is a C 2 -C 14 alkenyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • R 2 is a C 2 -C 14 alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • R 2 is a C 1 -C 5 alkyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • R 2 is a C 2 -C 5 alkenyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • R 2 is a C 2 -C 5 alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • R 2 is aryl
  • Y is —NHC(O)—.
  • Y is —N(CH 3 )C(O)—.
  • Y is —C(O)NH—.
  • Y is —C(O)N(CH 3 )—.
  • Y is —S—.
  • Y is —S(O)—.
  • Y is —(SO 2 )—.
  • Y is —O—.
  • Y is —NH—.
  • Y is —N(CH 3 )—.
  • Y is —OC(O)—.
  • R 6 is a C 2 -C 6 alkyl.
  • R 6 is a C 2 -C 6 alkenyl.
  • R 6 is a C 2 -C 6 alkynyl.
  • R 3 , R 4 , and R 5 are methyl.
  • R 3 , R 4 , and R 5 are ethyl.
  • R 3 and R 4 together form an aliphatic or heterocyclic ring having five or six ring atoms and R 5 is methyl or ethyl.
  • Exemplary compounds of formula I-IV useful in the methods of the invention include, but are not limited to, 3-dodecanamido-2-ethoxypropyl-1-phosphocholine, 3-decanamido-2-ethoxypropyl-1-phosphocholine, 3-decanamido-2-decyloxypropyl-1-phosphocholine, 3-dodecanamido-2-octyloxypropyl-1-phosphocholine, 3-dodecanamido-2-dodecyloxypropyl-1-phosphocholine, or 3-dodecanamido-2-butyloxy-1-phosphocholine; or a combination thereof.
  • the compounds used in the methods of the invention also include compounds of Formula AA: and pharmaceutically acceptable salts or prodrugs thereof,
  • X 1 is —NHC(O)—.
  • X 1 is —N(CH 3 )C(O)—.
  • X 1 is —C(O)NH—.
  • X 1 is —C(O)N(CH 3 )—.
  • X 1 is —NH—
  • X 1 is —N(CH 3 )—.
  • X 2 is —NHC(O)—.
  • X 2 is —N(CH3)C(O)—.
  • X 2 is —C(O) N (CH 3 )—.
  • X 2 is —S—.
  • X 2 is —S(O)—.
  • X 2 is —(SO 2 )—.
  • X 2 is —O—.
  • X 2 is —NH—.
  • X 2 is —N(CH 3 )—.
  • Y 1 is —(O)—.
  • Y 1 is —S—.
  • Y 1 is —Se—.
  • Y 2 is —O—.
  • Y 2 is —S—.
  • Y 2 is —Se—.
  • Z is —O—.
  • Z is —S—.
  • Z is —Se—.
  • Z is —NH—.
  • Z is —NR—.
  • W is —O—.
  • W is —S—.
  • W is —NH—.
  • W is —NR′—.
  • R 1 is a C 1 -C 22 alkyl optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • R 1 is a C 1 -C 12 alkyl optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • R 1 a C 2 -C 22 alkenyl optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • R 1 is a C 2 -C 12 alkenyl optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • R 1 a C 2 -C 22 alkynyl optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • R 1 is a C 2 -C 12 alkynyl optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • R 2 a C 1 -C 22 alkyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R′′, —C(O)N(R′)(R′′), —COOH, or —COOR′.
  • R 2 is a C 1 -C 12 alkyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R′′, —C(O)N(R′)(R′′), —COOH, or —COOR′.
  • R 2 a C 1 -C 5 alkyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R′′, —C(O)N(R′)(R′′), —COOH, or —COOR′.
  • R 2 is a C 2 -C 22 alkenyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R′′, —C(O)N(R′)(R′′), —COOH, or —COOR′.
  • R 2 is a C 2 -C 12 alkenyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R′′, —C(O)N(R′)(R′′), —COOH, or —COOR′.
  • R 2 is a C 2 -C 5 alkenyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R′′, —C(O)N(R′)(R′′), —COOH, or —COOR′.
  • R 2 is a C 2 -C 22 alkynyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R′′, —C(O)N(R′)(R′′), —COOH, or —COOR′.
  • R 2 is a C 2 -C 12 alkynyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R′′, —C(O)N(R′)(R′′), —COOH, or —COOR′.
  • R 2 is a C 2 -C 5 alkynyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R′′, —C(O)N(R′)(R′′), —COOH, or —COOR′.
  • R 6 is a C 2 -C 6 alkyl.
  • R 6 is —CH 2 —.
  • R 6 is —CH 2 —CH 2 —.
  • R 6 is a C 2 -C 6 alkenyl.
  • R 6 is a C 2 -C 6 alkynyl.
  • R 3 , R 4 , and R 5 are each independently a C 1 -C 6 alkyl.
  • each R 3 , R 4 and R 5 is independently a methyl or ethyl.
  • R 3 and R 4 together form a heterocyclic ring having between three and seven ring atoms and R 5 is an alkyl group.
  • R 3 and R 4 together form a heterocyclic ring having between three and seven ring atoms and R 5 is methyl.
  • R 3 and R 4 together form a heterocyclic ring having between three and seven ring atoms and R 5 is ethyl.
  • each R′ and R′′ is independently a C 1 -C 22 alkyl group.
  • compounds useful in the methods of the invention include compounds of Formula AA-1: and pharmaceutically acceptable salts or prodrugs thereof,
  • R 1 is a C 1 -C 12 alkyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • R 1 is a C 2 -C 12 alkenyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • R 1 is a C 2 -C 12 alkynyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • R 1 is a C 1 -C 5 alkyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • R 1 is a C 2 -C 5 alkenyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • R 1 is a C 2 -C 5 alkynyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • X 1 is —NHC(O)—.
  • X 1 is —N(CH 3 )C(O)—.
  • X 1 is —C(O)NH—.
  • X 1 is —C(O)N(CH 3 )—.
  • X 1 is —NH—.
  • X 1 is —N(CH 3 )—.
  • R 2 is a C 1 -C 12 alkyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • R is a C 2 -C 12 alkenyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • R 2 is a C 2 -C 12 alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • R is a C 1 -C 5 alkyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • R is a C 2 -C 5 alkenyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • R is a C 2 -C 5 alkynyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • X 2 is —NHC(O)—.
  • X 2 is —N(CH 3 )C(O)—
  • X 2 is —C(O)N(CH 3 )—.
  • X 2 is —S—.
  • X 2 is —S(O)—.
  • X 2 is —(SO 2 )—.
  • X 2 is —O—.
  • X 2 is —NH—.
  • X 2 is —N(CH 3 )—.
  • R 6 is a C 2 -C 6 alkenyl.
  • R 6 is a C 2 -C 6 alkynyl.
  • each R 3 , R 4 , and R 5 is independently methyl or ethyl.
  • R 3 and R 4 together form a heterocyclic ring having five or six ring atoms and R 5 is methyl.
  • R 3 and R 4 together form a heterocyclic ring having five or six ring atoms and R 5 is ethyl.
  • compounds useful in the methods of the invention include compounds of Formula AA-1: and pharmaceutically acceptable salts or prodrugs thereof,
  • one or more alkyl groups is substituted.
  • X 1 is —NHC(O)—.
  • X 1 is —N(CH 3 )C(O)—.
  • X 1 is —C(O)NH—.
  • X 1 is —C(O)N(CH 3 )—.
  • X 1 is —NH—.
  • X 1 is —N(CH 3 )—.
  • X 2 is —NHC(O)—.
  • X 2 is —N(CH 3 )C(O)—
  • X 2 is —C(O)N(CH 3 )—.
  • X 2 is —S—.
  • X 2 is —S(O)N.
  • X 2 is —(SO 2 )—.
  • X 2 is —O—.
  • X 2 is —NH—.
  • X 2 is —(NCH 3 )—
  • R 1 is a C 1 -C 12 alkyl.
  • R 1 is a C 2 -C 12 alkenyl.
  • R 1 is a C 2 -C 12 alkynyl.
  • R 2 is a C 1 -C12 alky
  • R 2 is a C 2 -C 12 alkenyl.
  • R 2 is a C 2 -C 12 alkynyl.
  • At least one of R 1 or R 2 is a C 1 -C 3 alkyl, C 2 -C 3 alkenyl, or C 2 -C 3 alkynyl.
  • At least one of R 1 or R 2 is a C 1 -C 3 alkyl.
  • At least one of R 1 or R 2 is a C 2 -C 3 alkenyl.
  • At least one of R 1 or R 2 is a C 2 -C 3 alkynyl group.
  • R 2 is a C 1 -C 5 alkyl.
  • R 2 is a C 2 -C 5 alkenyl.
  • R 2 is a C 2 -C 5 alkynyl group.
  • R 6 is a C 2 -C 6 alkyl.
  • R 6 is a C 2 -C 6 alkenyl.
  • R 6 is a C 2 -C 6 alkynyl.
  • the compounds used in the methods of the invention also include compounds of Formula BB-1: and pharmaceutically acceptable salts or prodrugs thereof.
  • the compounds used in the methods of the invention also include compounds of Formula BB-2: and pharmaceutically acceptable salts or prodrugs thereof.
  • the compounds used in the methods of the invention also include compounds of Formula BB-3: and pharmaceutically acceptable salts or prodrugs thereof.
  • the compounds used in the methods of the invention also include compounds of Formula BB-4: and pharmaceutically acceptable salts or prodrugs thereof.
  • the compounds used in the methods of the invention also include the phospholipids compounds disclosed in PCT publication WO 91/09602 (Boehringer Mannheim), which is incorporated herein in its entirety, and in particular phospholipids of the formula: and pharmaceutically acceptable salts or prodrugs thereof,
  • Y is an oxygen or a sulphur atom.
  • the compounds used in the methods of the invention also include the phospholipid compounds disclosed in WO 91/05558 (Boehringer Mannheim), which is incorporated herein in its entirety, and in particular phospholipids of the formula: and pharmaceutically acceptable salts or prodrug thereof,
  • the compounds used in the methods of the invention also include the phospholipid compounds disclosed in U.S. Pat. No. 4,444,766 (Boehringer Mannheim), which is incorporated herein in its entirety, and in particular phospholipids of the formula: and pharmaceutically acceptable salts or prodrug thereof,
  • exemplary compounds include any of the compounds disclosed in Ouyang et al., Journal of Medicinal Chemistry 45:2857-2866 (2002), the disclosure of which is hereby incorporated by reference.
  • Other compounds that may be used, alone or in combination, for the treatment of RSV, as disclosed herein, include compounds disclosed in U.S. Pat. No. 5,614,548, U.S. Pat. No. 5,962,437, and U.S. Pat. No. 5,770,584, the disclosures of which are hereby incorporated by reference.
  • the invention also provides the use of a compound of the invention, optionally with a pharmaceutical acceptable carrier or diluent, for the manufacture of a medicament for the treatment of a host infected with RSV.
  • Alkylamidophosphocholines may be prepared according to the method disclosed in Ouyang et al., Journal of Medicinal Chemistry 45(13): 2857-2866 (2002), and as described in Example 3 and FIG. 1 .
  • 3-Alkylamido-2-alkoxypropylphosphocholine is obtained by reacting commercially available 3-amino-1,2-propanediol with the appropriate acid chloride or anhydride. The primary alcohol is protected, and the secondary alcohol is alkylated with an alkyl bromide. The primary alcohol is deprotected, and then reacted with 2-bromoethyl dichiorophosphate and trimethylamine, to obtain the 3-alkylamido-2-alkoxypropylphosphocholine compound.
  • the compounds of the invention can also be prepared using the methods disclosed in Morris-Natschke S L, Gumus F, Marasco C J, Meyer K L, Marx M, Piantadosi, Layne M D, Modest E J, “Synthesis of Phosphocholine and Quaternary Amine Ether Lipids and Evaluation of In Vitro Antineoplastic Activity,” Journal of Medicinal Chemistry, 36:2018-2025 (1993); Piantadosi C., Marasco C. J., Morris-Natschke S. L., Meyer K. L., Gumus F., Surles J. R., Ishaq K.
  • salts are acid addition salts formed with inorganic acids, for example, hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids and the like; salts formed with organic acids such as acetic, oxalic, tartaric, succinic, maleic, fumaric, gluconic, citric, malic, methanesulfonic, p-toluenesulfonic, napthalenesulfonic, and polygalacturonic acids, and the like; salts formed from elemental anions such as chloride, bromide, and iodide; salts formed from metal hydroxides, for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, and magnesium hydroxide; salts formed from metal carbonates, for example, sodium carbonate, potassium carbonate, calcium carbonate, and magnesium carbonate; salts formed from metal bicarbonates, for example, sodium bicarbonate and potassium bicarbonate; salts formed from metal sulfates,
  • the compounds of the invention may be formulated as pharmaceutical compositions and administered to a host, such as a human patient, by a chosen route of administration.
  • Pharmaceutical compositions that are useful in the methods of the invention can be prepared, packaged, or sold in a variety of formulations which can be suitable for one or more routes of administration such as, for example, oral, intravenous, intramuscular, topical, subcutaneous, rectal, vaginal, parenteral, pulmonary, intranasal, buccal, ophthalmic, or another route of administration.
  • the active materials can be administered in liquid or solid form.
  • Other contemplated formulations include projected nanoparticles, liposomal preparations, resealed erythrocytes containing the active ingredient, and immunologically-based formulations.
  • compositions are principally directed to pharmaceutical compositions which are suitable for ethical administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to hosts of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and perform such modification with merely ordinary, if any, experimentation. Subjects to which administration of the pharmaceutical compositions of the invention is contemplated include, but are not limited to, humans and other primates and mammals including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, and dogs.
  • the compounds of the invention may be systemically administered (e.g. orally) in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They can be enclosed in hard or soft shell gelatin capsules, compressed into tablets, or incorporated directly into the food of the patient's diet.
  • a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier.
  • the active compound can be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • the concentration of active compound in the drug composition will depend on absorption, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
  • the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
  • Pharmaceutically compatible binding agents, and/or adjuvant materials may also be included as part of the composition.
  • compositions and preparations should contain at least 0.1% (w/w) of active compound.
  • the percentage of the compositions and preparations can, of course, be varied, for example from about 0.1% to nearly 100% of the weight of a given unit dosage form.
  • the amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained upon administration.
  • the tablets, froches, pills, capsules, and the like may also contain one or more of the following: binders, such as microcrystalline cellulose, gum tragacanth, acacia, corn starch, or gelatin; excipients, such as dicalcium phosphate, starch or lactose; a disintegrating agent, such as corn starch, potato starch, alginic acid, primogel, and the like; a lubricant, such as magnesium stearate or Sterotes; a glidant, such as colloidal silicon dixoide; a sweetening agent, such as sucrose, fructose, lactose, saccharin, or aspartame; a flavoring agent such as peppermint, methylsalicylate, oil of wintergreen, or cherry flavoring; and a peptide antiviral agent, such as envuvirtide (FuzeonTM).
  • binders such as microcrystalline cellulose, gum tragacanth, acacia, corn
  • the unit dosage form When the unit dosage form is a capsule, it can contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules can be coated with gelatin, wax, shellac, sugar, and the like.
  • a syrup or elixir can contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye, and flavoring such as cherry or orange flavor.
  • any material used in preparing a unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed.
  • the active compound may be incorporated into sustained-release preparations and devices.
  • the compounds of the invention thereof may also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, antiinflammatories, protease inhibitors, or other nucleoside or nonnucleoside antiviral agents.
  • Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application may include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the parental preparation may be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers may be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylacetic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials may also be obtained commercially from Alza Corporation.
  • the active compound may be administered orally, intravenously or intraperitoneally by infusion or injection.
  • Solutions of the active compound or its salts may be prepared in water, optionally mixed with a non-toxic surfactant.
  • Dispersions may be prepared in glycerol, liquid polyethylene glycols, triacetin, mixtures thereof, and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent growth of microorganisms.
  • compositions suitable for injection or infusion may include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes.
  • the ultimate dosage form should be sterile, fluid, and stable under conditions of manufacture and storage.
  • the liquid carrier or vehicle may be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
  • the proper fluidity may be maintained, for example, by formation of liposomes, by the maintenance of the required particle size (in the case of dispersions) or by use of one or more surfactants.
  • Microbial growth may be prevented using various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, buffers, or sodium chloride.
  • Prolonged absorption of the injectable compositions may be achieved using agents which delay absorption, for example, aluminum monostearate and gelatin.
  • Liposomal suspensions are also preferred as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
  • liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container.
  • appropriate lipid(s) such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol
  • aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives is then introduced into the container.
  • the container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
  • Sterile injectable solutions are prepared by incorporating the active compound in the required amount in an appropriate solvent, optionally with one or more of the other ingredients enumerated above, followed by filter sterilization.
  • preferred methods of preparation include vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient and any additional desired ingredient present in the previously-sterile-filtered solution(s).
  • a pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for rectal administration.
  • a composition may be in the form of, for example, a suppository, a retention enema preparation, and a solution for rectal or colonic irrigation.
  • Suppository formulations may be made by combining the active ingredient with a non-irritating pharmaceutically acceptable excipient which is solid at ordinary room temperature (i.e. about 20° C.) and which is liquid at the rectal temperature of the subject (i.e. about 37° C. in a healthy human).
  • Suitable pharmaceutically acceptable excipients include, but are not limited to, cocoa butter, polyethylene glycols, and various glycerides.
  • Suppository formulations may further comprise various additional ingredients including, but not limited to, antioxidants and preservatives.
  • Retention enema preparations or solutions for rectal or colonic irrigation may be made by combining the active ingredient with a pharmaceutically acceptable liquid carrier.
  • enema preparations may be administered using, and may be packaged within, a delivery device adapted to the rectal anatomy of the subject.
  • Enema preparations may further comprise various additional ingredients including, but not limited to, antioxidants and preservatives.
  • a pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for vaginal administration.
  • a composition may be in the form of, for example, a suppository, an impregnated or coated vaginally-insertable material such as a tampon, a douche preparation, or a solution for vaginal irrigation.
  • Methods for impregnating or coating a material with a chemical composition include, but are not limited to, methods of depositing or binding a chemical composition onto a surface, methods of incorporating a chemical composition into the structure of a material during the synthesis of the material (i.e. such as with a physiologically degradable material), and methods of absorbing an aqueous or oily solution or suspension into an absorbent material, with or without subsequent drying.
  • Douche preparations or solutions for vaginal irrigation may be made by combining the active ingredient with a pharmaceutically acceptable liquid carrier.
  • douche preparations may be administered using, and may be packaged within, a delivery device adapted to the vaginal anatomy of the subject.
  • Douche preparations may further comprise various additional ingredients including, but not limited to, antioxidants, antibiotics, antifungal agents, and preservatives.
  • a pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for pulmonary administration via the buccal cavity.
  • a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers, and preferably from about 1 to about 6 nanometers.
  • Such compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant may be directed to disperse the powder or using a self-propelling solvent/powder-dispensing container such as a device comprising the active ingredient dissolved or suspended in a low-boiling propellant in a sealed container.
  • such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. More preferably, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers.
  • Dry powder compositions preferably include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.
  • Low boiling propellants generally include liquid propellants having a boiling point of below 65° F. at atmospheric pressure.
  • the propellant may constitute 50 to 99.9% (w/w) of the composition, and the active ingredient may constitute 0.1 to 20% (w/w) of the composition.
  • the propellant may further comprise additional ingredients such as a liquid non-ionic or solid anionic surfactant or a solid diluent (preferably having a particle size of the same order as particles comprising the active ingredient).
  • compositions of the invention formulated for pulmonary delivery may also provide the active ingredient in the form of droplets of a solution or suspension.
  • Such formulations may be prepared, packaged, or sold as aqueous or dilute alcoholic solutions or suspensions, optionally sterile, comprising the active ingredient, and may conveniently be administered using any nebulization or atomization device.
  • Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, or a preservative such as methylhydroxybenzoate.
  • the droplets provided by this route of administration preferably have an average diameter in the range from about 0.1 to about 200 nanometers.
  • formulations described herein as being useful for pulmonary delivery are also useful for intranasal delivery of a pharmaceutical composition of the invention.
  • Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 to 500 micrometers. Such a formulation is administered in the manner in which snuff is taken i.e. by rapid inhalation through the nasal passage from a container of the powder held close to the nares.
  • Formulations suitable for nasal administration may, for example, comprise from about as little as 0.1% (w/w) and as much as 100% (w/w) of the active ingredient, and may further comprise one or more of the additional ingredients described herein.
  • a pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for ophthalmic administration.
  • Such formulations may, for example, be in the form of eye drops including, for example, a 0.1-1.0% (w/w) solution or suspension of the active ingredient in an aqueous or oily liquid carrier.
  • Such drops may further comprise buffering agents, salts, or one or more other of the additional ingredients described herein.
  • Other ophthalmalmically-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form or in a liposomal preparation.
  • the present compounds can be applied in pure form, i.e., as a liquid.
  • a dermatologically acceptable carrier which may be a solid or a liquid.
  • Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina, and the like.
  • Useful liquid carriers include water, alcohols, glycols, and blends of two or more of these, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.
  • Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize properties for a given use.
  • the resulting liquid compositions can be applied using absorbent pads, used to impregnate bandages or other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
  • Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses, or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
  • Examples of useful dermatological compositions which can be used to deliver the compounds of the invention to the skin are disclosed in Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).
  • the invention includes pharmaceutical compositions comprising one or more compounds of the invention or any combination thereof, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is adapted for oral, topical, or parenteral administration to a mammal, such as a human, and comprises one or more compounds of the invention, or any combination thereof, or a pharmaceutically acceptable salt thereof, in an amount effective to treat RSV.
  • treatment of RSV can mean, for example, any one or more of the following: inhibiting the replication of the virus, reducing the virus load within a patient, inhibiting formation of infectious progeny virus, inhibiting infectiousness of virus, killing cells harboring virus, interfering with one or more stages of the virus life cycle, inhibiting one or more viral enzymes or inducing production of non-infectious virus particles that can activate an immune response against infectious virus (e.g. autovaccination).
  • Useful dosages of the compounds of the invention for inclusion in the pharmaceutical compositions of the invention can be determined by comparing in vitro activity and in vivo activity of the compounds in appropriate animal models. Methods for the extrapolation of effective dosages in mice and other animal models to humans are known in the art (see, for example, U.S. Pat. No. 4,938,949).
  • the concentration of the compound(s) of the invention in a liquid composition will range from about 0.1% to about 95% by weight, preferably from about 0.5 % to about 25% by weight.
  • concentration in a semi-solid or solid composition such as a gel or a powder will range from about 0.1% to 100% by weight, preferably about 0.5% to about 5 % by weight.
  • Single doses for intravenous injection, subcutaneous, intramuscular or topical administration, infusion, ingestion or suppository will generally be from about 0.001 to about 5000 mg, and be administered from about 1 to about 3 times daily, to yield levels of about 0.01 to about 500 mg/kg, for adults.
  • the invention also includes one or more compounds of the invention, or any combination thereof, in an amount effective to inhibit RSV replication in a host.
  • the compound of course is therefore useful for inhibiting virus replication in a cell or neutralization (i.e. inactivation) of extracellular virus.
  • the invention includes one or more compound of the invention present as a pharmaceutically acceptable salt, or any combination thereof, wherein the compound is present in an amount effective to inhibit RSV replication in a host.
  • to inhibit RSV replication in a host means to reduce the virus load in a host to a level which is lower than the level of the virus load in an otherwise identical mammal which was not administered the compound.
  • virus load in a mammal is reduced by about 1 to 12 log 10 or more relative to an otherwise identical mammal which was not administered the compound.
  • Virus load in a mammal can be assessed by a number of methods known in the art such as, for example, obtaining a tissue or fluid sample from the mammal and assessing the amount of virus or viral components in the mammal contained therein using technology which is either virological, immunological, biochemical or molecular biological in nature and which is well known to the skilled artisan and which are described elsewhere herein. Inhibition of RSV replication in a cell is assessed using similar or identical assays as those used to assess virus load in a mammal.
  • the invention also includes a kit for administering a composition of the invention (e.g. a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention) to a host for treatment of RSV infection.
  • a composition of the invention e.g. a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention
  • the host is a human.
  • the kit comprises the composition of the invention and an instructional material, which describes adventitially administering the composition to the mammal by any of the routes of administration described herein.
  • this kit comprises a (preferably sterile) solvent suitable for dissolving or suspending the composition of the invention prior to administering the compound to the mammal.
  • an ” instructional material includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the composition of the invention in the kit for any one or more of the following: effecting treatment of a RSV infection in a mammal or in a cell or alleviation or treatment of the symptoms of a RSV infection in the mammal.
  • the instructional material of the kit of the invention may, for example, be affixed to a container which contains the composition of the invention or be shipped together with a container which contains the composition. Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and the composition be used cooperatively by the recipient.
  • the invention also includes a kit for inhibition of RSV replication in a cell.
  • the kit comprises a composition of the invention, which can be one or more compounds of the invention, or a pharmaceutical composition comprising one or more compounds of the invention or any combination thereof.
  • the kit also includes an instructional material.
  • inhibition of RSV replication in a cell means a reduction in RSV replication in a cell to a level lower than the level in an otherwise identical cell which was not administered the composition of the invention.
  • the reduction in RSV replication is by about 90 to about 99.9% relative to the otherwise identical cell which was not administered the composition of the invention.
  • the level of RSV replication in a cell and therefore RSV load in a mammal that is also being assessed can be assessed by any one of numerous methods known to the skilled artisan.
  • the level of RSV replication in a cell can be assessed by evaluating the number of RSV particles or amount of a viral component, such as a viral protein, a viral enzyme, or viral nucleic acid, in the cell or in fluid or debris associated with the cell.
  • the number of infectious virus particles in a cell can be evaluated, for example, in a plaque assay.
  • the level of a viral component such as a viral protein or enzyme in a cell can be evaluated using standard analytical techniques of protein biochemistry, such as, for example, using an activity assay for a viral enzyme, or using Western blotting or quantitative gel electrophoresis for a viral protein.
  • Viral nucleic acid levels in a cell can be evaluated using standard analytical techniques such as Northern blotting and Southern Blotting or quantitation by polymerase chain reaction (PCR).
  • the invention includes methods for treatment of a RSV infection in a host.
  • the methods comprise administering to the host one or more compounds of the invention, or any combination thereof, or a pharmaceutically acceptable salt thereof, in an amount effective to treat the virus infection.
  • the compound may be administered by any of the methods described herein.
  • the host is a human.
  • the invention also includes methods of treating a RSV infection in a host by contacting the RSV in vitro, in vivo or ex-vivo with one or more compounds of the invention, or any combination thereof, or a pharmaceutically acceptable salt thereof, in an amount effective to treat the RSV infection (e.g. to inhibit virus replication, infectivity, life cycle processes or pathogenesis).
  • Methods for testing the antiviral activity of a compound in-vitro are known to the skilled artisan, and are described, for example, in Kucera et al., 1990, AIDS Res. and Human Retrovir. 6:494.
  • the invention further includes methods of using one or more compounds of the invention, or any combination thereof, or a pharmaceutically acceptable salt thereof, in medical therapy (preferably for use in treating a virus infection) or for the manufacture of a medicament useful for the treatment of a virus infection.
  • the invention also includes methods of inhibiting RSV replication in a cell.
  • the ability of the active compounds to inhibit the growth of RSV was determined using a standard plaque assay with Hep-2 cell monolayers.
  • the cell monolayers were infected with RSV (Long strain obtained from the American Tissue Culture Catalog, Cat# VR-26). After one hour of virus attachment, the cells were overlaid with medium containing methyl cellulose with or without serial concentrations of compound (0.4-50 ⁇ M). Each concentration was tested in triplicate.
  • KPC-15 3-dodecylamido-2-ethoxypropylphosphocholine
  • KPC-11 decylamido-2-ethoxypropylphosphocholine
  • Alkylamidophosphocholine compounds are synthesized as described in Ouyang et al., Journal of Medicinal Chemistry, 45 :2857-2866 (2002).
  • the 3-alkylamido-2-alkoxypropylphosphocholine is obtained by reacting commercially available 3-amino-1,2,-propanediol with the appropriate acid chloride or anhydride.
  • the primary alcohol is protected, and the secondary alcohol is alkylated with an alkyl bromide.
  • the primary alcohol is deprotected and then reacted with 2-bromoethyl dichlorophosphate and trimethylamine to obtain the 3-alkylamido-2-alkoxypropylphosphocholine compound.
  • FIG. 1 describes the chemical synthesis of R, S, and racemic KPC-15 and shows there is a chiral center on the C-2 position of the three carbon backbone.
  • 3-nonylamido-2-ethoxypropylphosphocholine also was synthesized according to this method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention includes compounds useful for inhibiting RSV replication and treating a host infected with RSV. The invention also includes methods of treating a host infected with RSV by administering to the host an anti-RSV effective amount of a compound of the invention.

Description

    1. FIELD OF THE INVENTION
  • This invention relates generally to methods and compositions for the treatment of respiratory syncytial viral infections.
    • 2. BACKGROUND OF THE INVENTION
  • Respiratory syncytial virus (RSV) is a negative-strand RNA virus belonging to the family, Paramyxoviridae and to the genus, pneumovirus. The structure and composition of RSV have been described in detail. (Domawchowske et al., Clinical Microbiology Review 12:298-309 (1999)). Two major subgroups of RSV, type A and B, have been identified, as well as antigenic variants within each subgroup (Anderson;, L. J. et al., J Inf Dis 151:626-633 (1985); Mufson, M. A. et al., J Gen Virol 66:2111-2124 (1985)).
  • RSV is a major human pathogen, responsible for respiratory infection in patients of all ages. Typically, RSV infections remain localized to the upper respiratory tract, causing profuse rhinorrhea, nasal congestion, pharyngitis, cough and fever. In some patients, however, infection spreads to the lower respiratory tract. Severe lower respiratory tract disease (e.g., pneumonia, bronchiolitis) results, and typically requires hospitalization and breathing support. In some circumstances, RSV may be fatal.
  • Infants and young children, as well as immunocompromised patients and the elderly, are particularly at risk for serious respiratory illness related to RSV infection. Premature infants, as well as young children with chronic heart and lung disease, are at greatest risk for serious complications from RSV infection. Yet, 75% of the hospitalizations for RSV infection occur in infants and children that were previously healthy and without risk factors other than age. Approximately 100,000 children are hospitalized annually in the U.S. with severe cases of pneumonia and bronchiolitis resulting from an RSV infection (Hall, C. B. et al., N Engl J Med 344:1917-1928 (2001)). Moreover, RSV is responsible for hundreds of deaths in infants and young children each year.
  • RSV is highly contagious. Spread person to person through infected nasal and oral secretions, RSV can also live on surfaces for hours. Typically, RSV occurs in epidemics that last up to 4 months, from late fall through early spring. Children in day-care centers and preschools are at significant risk, and the elderly in hospitals and nursing homes are particularly vulnerable. School-aged children are commonly implicated in the spread of the disease, both to their younger siblings and their parents.
  • It has been recently reported that RSV accounts for 13.5-21.6% of the $2.25 billion in costs associated with hospitalization of infants with lower respiratory infections. The total costs are even greater, as these include treatment for other populations at high risk for RSV, including the elderly and the immunocompromised. RSV also affects healthy adults, and even in a milder form is associated with significant work absences. Re-infection with RSV is very common, forcing additional costs on the healthcare system. The health-related effects of initial infection in some populations, moreover, may be long term. Recent data indicates that RSV-induced lower respiratory tract infections in infants may be linked to the development of asthma or reactive airway disease in later childhood (Sigurs, N. et al., Am J Resp Crit Care Med 161:1501-1507 (2000)).
  • Despite the prevalence of RSV infection, and significant advances in scientific understanding, there are few approved treatments and even more controversy surrounding the proper management of high-risk populations. In general, most treatments for RSV are symptomatic. Supportive therapy may include monitoring, removal of secretions, intravenous hydration, administration of oxygen. Bronchodilators (e.g., metaproterenol or albuterol) and corticosteroids may be used, but most studies have concluded that there is insufficient evidence of therapeutic benefit except, perhaps, in certain subgroups (i.e., infants). Studies on vitamin A and interferon have also yielded disappointing results. Exogenous surfactant administration may be helpful in improving oxygenation in infants with severe RSV respiratory infection (Greenough, Acta Paediatr. Suppl. 2001, 436: 11-14).
  • Anti-viral therapy for RSV is limited to a single FDA-approved agent, Ribavirin (Virazole®). Ribavirin (1-beta-D-ribafuranosyl-1,2,4-traizole-3-carboxamide) is a synthetic nucleoside analog with broad spectrum antiviral activity against RSV, influenza, parainfluenza, adenovirus, measles, Lassa fever, and Hantaan viruses. Ribavirin is FDA-approved for use in very ill children hospitalized with severe RSV-related pneumonia. Yet, the use of Ribavirin even for this limited purpose is controversial in view of its mixed clinical history, cost and difficulty of administration and potential safety issues for secondary exposure. Extensive clinical trials on Ribavirin have generally failed to show that the drug reduces hospitalization time, length or severity of RSV bronchiolitis, or need for supportive therapies or mortality. As a result, routine use of Ribavirin, even in high-risk children with RSV infections, is no longer warranted.
  • Unlike treatment, prevention of RSV disease has been largely successful (Kimpen et al., Respiratory Research Vol. 3, Suppl 1, pp. S40-45 (2002)). Prevention is addressed primarily through passive immunization strategies that provide temporary immunity. The use of hyperimmune globulins such as RSV-IG (Respigam®; Medlmmune, Inc.) for the prevention of RSV in high-risk infants has been approved by the FDA. Drawbacks associated with the use of Respigam® include the long duration of intravenous administration (e.g., 6 hours), the considerable volume required (15 ml/kg), possible interference with normal vaccinations and high cost. The humanized murine monoclonal antibody palivizumab (Synagis®; Medlmmune, Inc.) has also been approved for the prevention of RSV lower respiratory tract disease. It is considerably easier to administer than RSV-IG (i.e., by monthly intramuscular injection) and doesn't interfere with normal vaccination, but it is also very costly.
  • While passive immunization has proven effective as a preventive for high-risk patients, most patients that develop RSV disease were previously healthy and did not exhibit risk factors other than age. There is currently no known vaccine for RSV. Challenges to development of a vaccine include, among others: (1) the possibility that vaccination will potentiate naturally occurring RSV disease; (2) the inability of many high-risk patients (e.g., newborns and very young children) to mount a protective immune response; and (3) the need to provide protection against multiple antigenic strains of RSV. Strategies for developing an RSV vaccine have included inactivated virus (e.g., formalin-inactivated vaccine), live-attenuated viruses (e.g., cold-adapted and/or temperature sensitive vaccine) and subunit vaccines (e.g., RSV F subunit vaccine).
  • U.S. Pat. No. 5,962,437 to Kucera et al. discloses methods of treating viral infections, in particular, HIV-1, hepatitis V virus, and herpes viruses. The compounds disclosed in U.S. Pat. No. 5,962,437 are phospholipids or phospholipid derivatives substituted at the 1-position with a C6-C18 alkyl group and at the 2-position with a C6-C14 alkyl group. The patent suggests that the compounds disclosed therein could also be used to treat RSV. However, given the complexities of the mechanism of replication of RSV and the pathology of RSV, compared with the other viruses listed in the patent, until the present invention, the successful treatment of RSV with the disclosed compounds could not have been predicted.
  • In light of the fact that RSV remains a serious public health threat, there remains a strong need to provide new effective pharmaceutical agents to treat humans infected with the virus. The ideal new pharmaceutical agent would be potent, long-acting and easy to administer. It is therefore an object of the present invention to provide new methods for the treatment of human patients and other hosts infected with RSV.
    • 3. SUMMARY OF THE INVENTION
  • The invention is directed to compounds of Formula I:
    Figure US20050187191A1-20050825-C00001
    and pharmaceutically acceptable salts or prodrugs thereof,
      • wherein:
      • R1 is —NHC(O)Y, where Y is C1-C22 alkyl, C2-C22 alkenyl, or C2-C22 alkynyl;
      • R2 is —OX, where X is C1-C22 alkyl, C2-C22 alkenyl, C2-C22 alkynyl; and
      • R3 is phosphocholine.
  • In one embodiment of the compound of formula I, Y and X are independently C1-C14 alkyl, C2-C14 alkenyl, or C2-C14 alkynyl.
  • In one embodiment of the compound of formula I, Y is —C10H21; and X is —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, or —C10H21.
  • In one embodiment of the compound of formula I, Y is —C11H23 and X is C1-C5 alkyl
  • In one embodiment of the compound of formula I, Y is —C9H19 and X is C9-C11 alkyl.
  • In one embodiment the compound of formula I is
    Figure US20050187191A1-20050825-C00002
    3-dodecanamido-2-ethoxypropyl-1-phosphocholine,
    Figure US20050187191A1-20050825-C00003
    3-decanamido-2-ethoxypropyl-1-phosphocholine,
    Figure US20050187191A1-20050825-C00004
    3-decanamido-2-decyloxypropyl-1-phosphocholine,
    Figure US20050187191A1-20050825-C00005
    3-dodecanamido-2-octyloxypropyl-1-phosphocholine,
    Figure US20050187191A1-20050825-C00006
    3-dodecanamido-2-dodecyloxypropyl-1-phosphocholine, or
    Figure US20050187191A1-20050825-C00007
    3-dodecanamido-2-butyloxy-1-phosphocholine.
  • The invention is also directed a compound of Formula II:
    Figure US20050187191A1-20050825-C00008
    and pharmaceutically acceptable salts or prodrugs thereof,
      • wherein:
      • M is C2-C4 alkyl;
      • X1 is —S—, —O—, —NH—, or —NHC(O)—;
      • R21 is C1-C20 straight chain alkyl, C2-C20 straight chain alkylene containing not more than four double bonds, or aryl;
      • R22 is C1-C20 straight chain alkyl, C2-C20 straight chain alkylene containing not more than four double bonds, or aryl; and
      • R23, R24, and R25 are each independently hydrogen, methyl, ethyl, propyl, or isopropyl.
  • In one embodiment, of the compound of Formula II,
      • M is —CH2CH2—; X1 is —NHC(O)—;
      • R21 is a C1-C16 straight chain alkyl or C2-C16 straight chain alkylene containing not more than one double bond;
      • R22 is a C1-C16 straight chain alkyl or C2-C16 straight chain alkylene containing not more than one double bond; and
      • R23, R24, and R25 are each independently hydrogen or methyl.
  • In one embodiment, of the compound of Formula II,
      • R21 is a C1-C16 straight chain alkyl or C2-C16 straight chain alkylene containing not more than one double bond; and
      • R22 is a C1-C5 straight chain alkyl or C2-C5 straight chain alkylene containing not more than one double bond.
  • In one embodiment, of the compound of Formula II, R21 is C9-C12 alkyl and R22 is C1-C12 alkyl.
  • In one embodiment, of the compound of Formula II, R21 is C9-C12 alkyl and R22 is C1-C5 alkyl.
  • In one embodiment, of the compound of Formula II, R21 is C9-C12 alkyl and R22 is C8-C12 alkyl.
  • The invention is also directed to a compound of Formula III:
    Figure US20050187191A1-20050825-C00009
    and pharmaceutically acceptable salts or prodrugs thereof,
      • wherein:
      • Y is —S—, —O—, —NH—, —N(CH3)—, —NHC(O)—, or —N(CH3)C(O)—;
      • R1 is C1-C18 alkyl, C2-C18 alkenyl, C2-C18 alkynyl, or aryl;
      • X is a covalent bond or methylene that is optionally substituted with a hydroxyl, C1-C20 alkyl, —O—(C1-C20 alkyl), —S—(C1-C20 alkyl), —C(O)N(C1-C20 alkyl), C2-C20 alkenyl, —O—(C2-C20 alkenyl), —S—(C2-C20 alkenyl), —C(O)N(C2-C20 alkenyl), C2-C20 alkynyl, —O—(C2-C20 alkynyl), —S—(C2-C20 alkynyl), or —C(O)N(C2-C20 alkynyl);
      • J is a C1-C4 alkyl optionally substituted from one to three times with methyl or ethyl; and
      • R2, R3, and R4 are independently hydrogen or C1-C3 alkyl.
  • In one embodiment, of the compound of Formula III,
      • Y is —NHC(O)—;
      • R1 is C6-C18 alkyl;
      • X is —C(H)(O—C1-C18 alkyl)- or —C(H)(O—C1-C18 alkenyl)-;
      • J is —CH2CH2—; and
      • R2, R3, and R4 are each methyl.
  • In one embodiment, of the compound of Formula III, R1 is —C11H23 and X is —C(H)(O—C1-C5 alkyl)- or —C(H)(O—C1-C5 alkenyl)-
  • In one embodiment, of the compound of Formula III, R1 is —C9H19 and X is —C(H)(OC2H5)—
  • In one embodiment, of the compound of Formula III, R1 is —C9H19 and X is —C(H)(OC10H21)—.
  • The invention is also directed to a compound of Formula IV:
    Figure US20050187191A1-20050825-C00010
    and pharmaceutically acceptable salts or prodrugs thereof,
      • wherein:
      • R1 is a C6-C18 alkyl, C6-C18 alkenyl, or C6-C18 alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino, or aryl;
      • X is —NHC(O)—, —N(CH3)C(O)—, —C(O)NH—, —C(O)N(CH3)—, —S—, —S(O)—, —(SO2)—, —O—, —NH—, and —N(CH3)—;
      • R2 is a C1-C14 alkyl, C2-C14 alkenyl, or C2-C14 alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino, or aryl;
      • Y is —NHC(O)—, —N(CH3)C(O)—, —C(O)NH—, —C(O)N(CH3)—, —S—, —S(O)—, —(SO2)—, —O—, —NH—, —N(CH3)—, or —OC(O)—;
      • R6 is a C2-C6 alkyl; C2-C6 alkenyl, or C2-C6 alkynyl; and
      • R3, R4, and R5 are independently methyl or ethyl, or R3 and R4 together form an aliphatic or heterocyclic ring having five or six ring atoms and R5 is methyl or ethyl.
  • In one embodiment, of the compound of Formula IV,
      • R2 is C1-C14 alkyl, C2-C14 alkenyl, or C2-C14 alkynyl,;
      • R6 is —CH2CH2—; and
      • R3, R4, and R5 are each independently CH3.
  • In one embodiment, of the compound of Formula IV, R2 is C1-C5 alkyl or C2-C5 alkenyl.
  • In one embodiment, of the compound of Formula IV, R1 is C8-C12 alkyl and R2 is C1-C12 alkyl.
  • In one embodiment, of the compound of Formula IV, R1 is C8-C12 alkyl and R2 is C1-C5 alkyl.
  • In one embodiment, of the compound of Formula IV, R1 is C8-C12 alkyl and R2 is C8-C12 alkyl
  • In one embodiment, of the compound of Formula IV,
      • X is —NHC(O), —N(CH3)C(O)—, —C(O)NH—, —C(O)N(CH3) and
      • Y is —O—, —NH—, or —N(CH3)—.
  • The invention is also directed to a compound of Formula AA-1:
    Figure US20050187191A1-20050825-C00011
    and pharmaceutically acceptable salts or prodrugs thereof,
      • wherein:
      • X1 is —NHC(O)—;
      • X2 is —O—;
      • R1 is —C1-C22 alkyl;
      • R is —C1-C22 alkyl;
      • R6 is —CH2CH2—; and
      • R3, R4, and R5 are methyl.
  • In one embodiment, of the compound of Formula AA-1,
      • R1 is —CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, —CH2CH2CH2CH2CH3, —(CH2)5CH3, —(CH2)6CH3, —(CH2)7CH3, —(CH2)8CH3, —(CH2)9CH3, —(CH2)10CH3, —(CH2)11CH3, —(CH2)12CH3 or —(CH2)13CH3; and
      • R2 is —CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, —CH2CH2CH2CH2Ch3, —(CH2)5CH3, —(CH2)6CH3, —(CH2)7CH3, —(CH2)8CH3, —(CH2)9CH3, —(CH2)10CH3, —(CH2)11CH3, —(CH2)12CH3 or —(CH2)13CH3.
  • In one embodiment, of the compound of Formula AA-1,
      • R1 is —(CH2)8CH3, —(CH2)9CH3, —(CH2)10CH3, —(CH2)11CH3; —(CH2)12CH3, or —(CH2)13CH3; and
      • R2 is CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, —CH2CH2CH2CH2CH3, —(CH2)5CH3, —(CH2)6CH3, or —(CH2)7CH3.
  • In one embodiment, of the compound of Formula AA-1,
      • R1 is —(CH2)5CH3, —(CH2)6CH3, —(CH2)7CH3, —(CH2)8CH3, —(CH2)9CH3, —(CH2)10CH3, —(CH2)11CH3, or —(CH2)12CH3; and
      • R2 is —(CH2)6CH3, —(CH2)7CH3, —(CH2)8CH3, —(CH2)9CH3, —(CH2)10CH3, —(CH2)11CH3, —(CH2)12CH3, or —(CH2)13CH3.
  • The invention also provides a method for treating a host infected with RSV. This method comprises administering to a host in need thereof an anti-RSV effective amount of compound of Formula I-IV or AA-1, or a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, the host is a mammal. In one embodiment, the host is a human.
  • The compound of Formula I-IV or AA-1, or a pharmaceutically acceptable salt or prodrug thereof can be administered orally, intravenously, parentally, intradermally, subcutaneously, topically, or by inhalation.
  • The invention further provides a method of inhibiting RSV replication in a cell. This method comprises administering to the cell, in an amount effective to inhibit replication of RSV in a cell, a compound of Formula I-IV or AA-1, or a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, the host is a mammal. In one embodiment, the host is a human.
  • The invention also provides pharmaceutical compositions comprising a compound of Formula I-IV or AA-1, or a pharmaceutically acceptable salt or prodrug thereof.
  • The invention also provides a kit comprising a compound of Formula I-IV or AA-1, or a pharmaceutically acceptable salt or prodrug thereof.
  • The invention also provides the use of a compound of Formula I -IV or AA-1, or a pharmaceutically acceptable salt or prodrug thereof, optionally with a pharmaceutical acceptable carrier or diluent, for the manufacture of a medicament for the treatment of a host infected with RSV.
    • 4. BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 illustrates a process that may be used generally for obtaining a 3-alkylamido-2-alkoxypropylphosphocholine.
    • 5. DETAILED DESCRIPTION OF THE INVENTION
  • Provided are methods and compositions for the treatment of RSV infection in humans and other host animals. The compounds useful for the treatment of RSV infection are alkylamidophosphocholine compounds or analogs thereof and pharmaceutically acceptable salts or prodrugs thereof (hereinafter “compounds of the invention”). The methods involve administering an effective amount of a compound of the invention, optionally in a pharmaceutically acceptable carrier, to a host in need thereof. The compounds of the invention can be used singly or in combination. The methods treat or retard the progression of clinical illness in an individual infected with RSV. The methods of treatment can be used to treat severe RSV lower respiratory tract infections including, but not limited to, the treatment of RSV bronchiolitis and pneumonia.
  • The invention also includes a method of inhibiting RSV replication in a cell. This method comprises administering to the cell, in an amount effective to inhibit replication of RSV in a cell, a compound of the invention.
  • Compounds of the invention that can be administered include, but are not limited to, 3-dodecanamido-2-ethoxypropyl-1-phosphocholine, 3-decanamido-2-ethoxypropyl-1-phosphocholine, 3-decanamido-2-decyloxypropyl-1-phosphocholine, 3-dodecanamido-2-octyloxypropyl-1-phosphocholine, 3-dodecanamido-2-dodecyloxypropyl-1-phosphocholine, 3-dodecanamido-2-butyloxy-1-phosphocholine, optionally in a pharmaceutically acceptable carrier. The compounds may possess anti-RSV activity or be metabolized to a compound or compounds that exhibit anti-RSV activity. Without wishing to be bound by theory, it is believed that the effectiveness of the compounds of the invention may be due to the fact that they are phosphocholine (PC) analogs which may provide a surfactant effect to assist in the removal of pulmonary secretions and improve oxygenation that is beneficial against RSV if administered by pulmonary administration.
  • Previous studies have established that a PC moiety is an essential component for a phospholipid to exhibit optimal antiviral activity (Piantadosi et al., 1991, J. Med. Chem. 34:1408-1414; Krugner-Higby et al., 1995, AIDS Res. & Human Retrovir. 11:705-712). Lipid compounds comprising phosphatidic acid, phosphoethanolamine, phosphoalkylpyridine, alcohol or quarternary amine salt moieties were less active, more toxic, exhibited much lower differential selectivities or some combination of these, relative to the corresponding PC lipids. In the compounds of the invention, a PC moiety is incorporated into the lipid backbone to provide compounds that exhibit optimal antiviral activity.
    • 5.1 DEFINITIONS
  • As used herein, RSV infection and related conditions include, but are not limited to, one or more conditions, such as acute respiratory illness, pneumonia, bronchiolitis (inflammation of the small airways of the lungs), tracheobronchitis (croup), and ostitis media (ear infections).
  • The term “treatment” as used herein, means an approach for obtaining beneficial or desired results including clinical results, such as, but not limited to, alleviation of symptoms of a disease or condition, diminishment of extent of a disease or condition, stabilization (i.e., not worsening) of a disease or condition, preventing spread of a disease or condition, preventing or reducing occurrence or recurrence of a disease or condition, delaying or slowing of a disease's or condition's progression, and reducing the incidence of a disease or condition or the symptoms of a disease or condition.
  • The articles “a” and “an” are used herein to refer to one or more than one (i.e., at least one) of the grammatical object of the article. By way of example, “an element” means on element or more than one element.
  • Compounds of the invention having a chiral center can exist in and be isolated in distinct optically active or racemic forms. The present invention encompasses racemic, optically active, and stereoisomeric forms, and all mixtures of such forms of a compound of the invention. Methods of preparing optically active forms of a compound are well known in the art and include, for example, resolution of a racemic mixture of the compound using recrystallization techniques, synthesis of the compound from optically active starting materials, chiral synthesis of the compound, and chromatographic separation of a racemic micture of the compound using a chiral stationary phase. The present invention also encompasses polymorphic forms and mixtures thereof.
  • Determining or assessing antiviral activity may be performed using standard tests described herein or other tests know in the art.
  • As used herein, the term “alkyl,” unless otherwise specified, means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon. Examples of alkyl include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, sec-pentyl, iso-pentyl, hexyl, iso-hexyl, sec-hexyl, heptyl, sec-heptyl, iso-heptyl, octyl, iso-octyl, sec-octyl, nonyl, iso-nonyl, sec-nonyl, undecyl, iso-undecyl, sec-undecyl, dodecyl, iso-dodecyl, sec-dodecyl, tridecyl, iso-tridecyl, sec-tridecyl, tetradecyl, iso-tetradecyl, sec-tetradecyl, pentadecyl, iso-pentadecyl, sec-pentadecyl, and eicosyl moieties.
  • As used herein, the term “C1-C3 alkyl” means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 1 to 3 carbon atoms.
  • As used herein, the term “C1-C4 alkyl” means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 1 to 4 carbon atoms.
  • As used herein, the term “C2-C4 alkyl” means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 2 to 4 carbon atoms.
  • As used herein, the term “C2-C6 alkyl” means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 2 to 6 carbon atoms.
  • As used herein, the term “C6-C18 alkyl” means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 6 to 18 carbon atoms.
  • As used herein, the term “C2-C14 alkyl” means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 2 to 14 carbon atoms.
  • As used herein, the term “C1-C22 alkyl” means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 1 to 22 carbon atoms.
  • As used herein, the term “C1-C20 alkyl” means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 1 to 20 carbon atoms.
  • As used herein, the term “C14-C18 alkyl” means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 14 to 18 carbon atoms.
  • As used herein, the term “C9-C30 alkyl” means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 9 to 30 carbon atoms.
  • As used herein, the term “alkenyl,” unless otherwise specified, means a straight chain or branched, acyclic or cyclic, hydrocarbon having at least 2 carbon atoms and including at least one carbon-carbon double bond. Examples of alkenyl include, but are not limited to, vinyl, allyl, 1-butenyl, 2-butenyl, isobutenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-1-butenyl, 2,3-dimethyl-2-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 2-decenyl, and 3-decenyl moieties.
  • As used herein, the term “C2-C22 alkenyl” means a straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 2 to 22 carbon atoms and including at least one carbon-carbon double bond.
  • As used herein, the term “C2-C20 alkenyl” means a straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 2 to 20 carbon atoms and including at least one carbon-carbon double bond.
  • As used herein, the term “C6-C18 alkenyl” means a straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 6 to 18 carbon atoms and including at least one carbon-carbon double bond.
  • As used herein, the term “C2-C14 alkenyl” means a straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 2 to 14 carbon atoms and including at least one carbon-carbon double bond.
  • As used herein, the term “C9-C30 alkenyl” means a saturated straight chain or branched, acyclic or cyclic, primary, secondary, or tertiary hydrocarbon having from 9 to 30 carbon atoms and including at least one carbon-carbon double bond.
  • As used herein, the term “alkynyl,” unless otherwise specified, means a straight chain or branched, acyclic hydrocarbon having at least 2 carbon atoms and including at least one carbon-carbon triple bond. Examples of alkynyl include, but are not limited to, acetylenyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1-butynyl, 4-pentynyl, 1-hexynyl, 2-hecynyl, 5-hexynyl, 1-heptynyl, 2-heptynyl, 6-heptynyl, 1-octynyl, 2-octynyl, 7-octynyl, 1-nonynyl, 2-nonynyl, 8-nonynyl, 1-decynyl, 2-decynyl, and 9-decynyl moieties.
  • As used herein, the term “C2-C22 alkynyl” means a straight chain or branched, acyclic primary, secondary, or tertiary hydrocarbon having from 2 to 22 carbon atoms and including at least one carbon-carbon triple bond.
  • As used herein, the term “C2-C20 alkynyl” means a straight chain or branched, acyclic primary, secondary, or tertiary hydrocarbon having from 2 to 20 carbon atoms and including at least one carbon-carbon triple bond.
  • As used herein, the term “C6-C18 alkynyl” means a straight chain or branched, acyclic primary, secondary, or tertiary hydrocarbon having from 6 to 18 carbon atoms and including at least one carbon-carbon triple bond.
  • As used herein, the term “C2-C14 alkynyl” means a straight chain or branched, acyclic primary, secondary, or tertiary hydrocarbon having from 2 to 14 carbon atoms and including at least one carbon-carbon triple bond.
  • As used herein, the term “C9-C30 alkynyl” means a saturated straight chain or branched, acyclic, primary, secondary, or tertiary hydrocarbon having from 9 to 30 carbon atoms and at least on carbon-carbon triple bond.
  • As used herein, the term “aryl,” unless otherwise specified, means phenyl, biphenyl, or napthyl, optionally substituted with one or more of halo, alkyl, alkenyl, alkynyl, —OH, —NH2, —NHR1, —NR1R1, —NH(aryl), —NH(aryl)(aryl), —O-alkyl, —O-alkenyl, —O-alkynyl, —O-aryl, nitro, cyano, —S-alkyl, —S-alkenyl, —S-alkynyl, —S-aryl, —NR1C(O)R1, —COOH, —SO3H, —COOR1, —OP(O)(OR1)2, —OP(O)(R1)(OR1), —OP(O)(R1)2, either unprotected or protected using a protecting group (as known to those skilled in the art, for example, as taught in Greene et al. Protective Groups in Organic Synthesis. Jogn Wiley and Sons, 2nd edition (1991)), wherein each R1 is independently hydrogen, alkyl, alkenyl, or alkynyl.
  • As used herein, the term “halo” or “halogen” as used herein means —Cl, —Br, —I, and —F.
  • As used herein, the term “amino” means —NH2.
  • As used herein, the term “oxo” means a methylene group wherein the two hydrogens of the methylene are replaced with double bond to oxygen.
  • As used herein, the term “heterocyclic ring,” unless otherwise specified, means a 3 to 10 membered monocyclic or bicyclic ring which is either saturated, unsaturated non-aromatic, or aromatic containing from 1 to 4 heteroatoms independently selected from nitrogen, which can be quaternized; oxygen; and sulfur, including sulfoxide and sulfone. The heterocycle ring can be attached by a nitrogen, sulfur, or carbon atom. Representative heterocycles include, but are not limited to, pyridyl, furyl, thiophenyl, pyrrolyl, oxazolyl, imidazolyl, thiazolyl, thiadiazolyl, isooxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl, pyrrolidinyl, piperidinyl, piperizinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, quinolinyl, isoquinolinyl, chromonyl, coumarinyl, indolyl, indolizinyl, benzo[b[furanyl, benzo[b]thiophenyl, indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, and carbazolyl.
  • As used herein, the term “heteroaromatic,” unless otherwise specified, means an aromatic heterocycle ring having between 5 and 10 ring atoms, including both monocyclic and bicyclic ring systems, wherein at least one carbon atom of one or both of the rings is replaced with a heteroatom independently selected from nitrogen, oxygen, and sulfur. Representative heteroaromatics include, but are not limited to, pyridyl, furyl, benzofutanyl, thiophenyl, benzothiophenyl, quinolynyl, pyrrolyl, indolyl, oxazolyl, benzooxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiadiazolyl, triazinyl, cinnolinyl, phthalazinyl, and quinazolinyl.
  • As used herein the term “cycloalkane ring” or “cycloalkyl,” unless otherwise specified, means a 3 to 14 membered monocyclic, bicyclic, or tricyclic hydrocarbon ring which is either saturated or unsaturated non-aromatic. Representative cycloalkane rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, indanyl, 1,2,3,4-tetrahydronaphthyl, perhydronaphthyl, 1,2,3,4-tetrahydroanthracenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cycloheptenyl, cyclohetadienyl, and cycloheptatrienyl.
  • As used herein the term “C3-C8 cycloalkyl” or “C3-C8 cycloalkane ring” means a 3 to 8 membered monocyclic hydrocarbon ring a which is either saturated or unsaturated non-aromatic. Representative C3-C8 cycloalkane rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • As used herein, the term “prodrug” means a compound that, when administered to an animal, is converted under physiological conditions to a compound of the invention.
  • As used herein, the term “anti RSV effective amount” means and amount effective for treating RSV.
  • The term “host”, as used herein, refers to a unicellular or multicellular organism in which the virus can replicate, including cell lines and animals, and preferably a human. Alternatively, the host can be carrying a part of the viral genome, whose replication or function can be altered by the compounds of the invention. The term host refers to infected cells, cells transfected with all or part of the RSV genome, and animals, in particular, primates (including chimpanzees) and humans. In most methods of the invention, the host is a human patient. Veterinary applications, in certain indications, however, are clearly encompassed by the present invention, such as in chimpanzees.
  • The term “pharmaceutical salt” refers to a salt that retains the desired biological activity of the parent compound and preferably does not impart undesired toxicological effects thereto. Examples of salts include, but are not limited to, (a) salts formed with cations such as sodium, potassium, NH4 +, magnesium, and calcium polyamines such as spermine and spermidine; (b) acid addition salts formed with inorganic acids including, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, and nitric acid; (c) salts formed with organic acids including, but not limited to, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid; and (d) salts formed from elemental anions such as chloride, bromide, and iodide.
    • 5.2 COMPOUNDS OF THE INVENTION
  • A variety of compounds may be used in the methods disclosed herein for the treatment of RSV. These compounds exhibit anti-RSV activity.
    • 5.2.1 COMPOUNDS OF FORMULA I
  • The compounds used in the methods of the invention include compounds of Formula I:
    Figure US20050187191A1-20050825-C00012
    and pharmaceutically acceptable salts or prodrugs thereof
      • wherein:
      • R1 is —NHC(O)Y, where Y is C1-C22 alkyl, C2-C22 alkenyl, or C2-C22 alkynyl;
      • R2 is —OX, where X is C1-C22 alkyl, C2-C22 alkenyl, or C2-C22 alkynyl; and
      • R3 is phosphocholine (—OPO3 −CH2CH2N+(CH3)3).
  • In one embodiment, Y is C1-C22 alkyl.
  • In one embodiment, Y is C2-C22 alkenyl.
  • In one embodiment, Y is C2-C22 alkynyl.
  • In one embodiment, X is C1-C22 alkyl.
  • In one embodiment, X is C2-C22 alkenyl.
  • In one embodiment, X is C2-C22 alkynyl.
  • In one embodiment, X is a C1-C5 alkyl.
  • In one embodiment, X is C2-C5 alkenyl.
  • In one embodiment, X is C2-C5 alkynyl.
  • In one embodiment, X is —C2H5 or —C10H21.
  • In one embodiment, X is —C2H5.
  • In one embodiment, Y is —C9H19 or —C11H23.
  • In one embodiment, Y is —C11H23, X is —C2H5, and R3 is phosphocholine.
  • In one embodiment, Y is —C9H19, X is —C2H5, and R3 is phosphocholine.
  • In one embodiment, Y is —C9H19, X is —C10H21, and R3 is phosphocholine.
    • 5.2.2 COMPOUNDS OF FORMULA II
  • The compounds used in the methods of the invention also include compounds of Formula II:
    Figure US20050187191A1-20050825-C00013
    and pharmaceutically acceptable salts or prodrugs thereof,
      • wherein:
      • M is a C2-C4 alkyl;
      • X1 is —S—, —O—, —NH—, or —NHC(O)—;
      • R21 is a C1-C20 straight chain alkyl, C2-C20 straight chain alkylene containing not more than four double bonds, or aryl;
      • R22 is a hydrogen, C1-C20 straight chain alkyl, or C2-C20 straight chain alkylene containing not more than four double bonds; and
      • R23, R24, and R25 are each independently either hydrogen, methyl, ethyl, propyl, or isopropyl.
  • In one embodiment, M is —CH2CH2—.
  • In one embodiment, M is —CH2CH2CH2—.
  • In one embodiment, M is —CH2CH2CH2CH2—.
  • In one embodiment, M is —CH2CH(CH3)—
  • In one embodiment, M is —CH(CH3)CH2—.
  • In one embodiment, M is —CH(CH3)CH2CH2—.
  • In one embodiment, M is —CH2CH(CH3)CH2—.
  • In one embodiment, M is —CH2CH2CH(CH3)—.
  • In one embodiment, M is —C(CH3)2—.
  • In one embodiment, M is —CH2C(CH3)2—.
  • In one embodiment, M is —C(CH3)2CH2—.
  • In one embodiment, X1 is —S—.
  • In one embodiment, X1 is —O—.
  • In one embodiment, X1 is —NH—.
  • In one embodiment, X1 is —NHC(O)—.
  • In one embodiment, R21 is a C1-C20 straight chain alkyl.
  • In one embodiment, R21 is a straight chain C2-C20 alkylene containing not more than four double bonds.
  • In one embodiment, R21 is aryl.
  • In one embodiment, R22 is a C1-C20 straight chain alkyl.
  • In one embodiment, R22 is a C2-C20 straight chain alkylene containing not more than four double bonds.
  • In one embodiment, R22 is a C1-C5 straight chain alkylene containing not more than four double bonds.
  • In one embodiment, R22 is a C1-C5 straight chain alkyl.
  • In one embodiment, R22 is hydrogen.
  • In one embodiment, R22 is methyl.
  • In one embodiment, R22 is ethyl.
  • In one embodiment, R23, R24, and R25 are methyl.
  • In one embodiment of Formula II:
    M is —CH2CH2—;
      • X1 is —NHC(O)—;
      • R21 is a C16-C18 straight chain alkyl or C16-C18 straight chain alkenyl containing not more than one double bond;
      • R22 is hydrogen, methyl, or ethyl; and
      • R23, R24, and R25 are each independently hydrogen or methyl.
  • In one embodiment of Formula II:
      • M is —CH2CH2—;
      • X1 is —NHC(O)—;
      • R21 is a C16-C18 straight chain alkyl or C16-C18 straight chain alkenyl containing not more than one double bond;
      • R22 is hydrogen, methyl, or ethyl; and
      • R23, R24, and R25 are each methyl.
  • In one embodiment of Formula II,
      • M is —CH2CH2—;
      • X1 is —NHC(O)—;
      • R21 is —C11H23 or —C9H19;
      • R22 is —C2H5 or —C10H21; and
      • R23, R24 and R25 are each methyl.
    5.2.3 COMPOUNDS OF FORMULA III
  • The compounds used in the methods of the invention also include compounds, of Formula III:
    Figure US20050187191A1-20050825-C00014
    and pharmaceutically acceptable salts or prodrugs thereof,
      • wherein:
      • Y is —S—, —O—, —NH—, —N(CH3)—, —NHC(O)—, or —N(CH3)C(O)—;
      • R1 is C1-C18 alkyl, C2-C18 alkenyl, C2-C18 alkynyl, or aryl;
      • X is a covalent bond or methylene that is optionally substituted with a hydroxyl, C1-C20 alkyl, —O—(C1-C20 alkyl), —S—(C1-C20 alkyl), —C(O)N(C2-C20 alkyl), C2-C20 alkenyl, —O—(C2-C20 alkenyl), —S—(C2-C20 alkenyl), —C(O)N(C2-C20 alkenyl), C2-C20 alkynyl, —O—(C2-C20 alkynyl), —S—(C2-C20 alkynyl), or —C(O)N(C2-C20 alkynyl);
      • J is a C1-C4 alkyl that is optionally substituted one to three times with methyl or ethyl; and
      • R2, R3, and R4 are independently hydrogen or C1-C3 alkyl.
  • In one embodiment, Y is —S—.
  • In one embodiment, Y is —O—.
  • In one embodiment, Y is —NH—.
  • In one embodiment, Y is —N(CH3)—.
  • In one embodiment, Y is —NHC(O)—.
  • In one embodiment, Y is —N(CH3)C(O)—.
  • In one embodiment, R1 is C1-C18 alkyl.
  • In one embodiment, R1 is C2-C18 alkenyl.
  • In one embodiment, R1 is C2-C18 alkynyl.
  • In one embodiment, R1 is C14-C18 alkyl.
  • In one embodiment, R1 is C14-C18 alkenyl.
  • In one embodiment, R1 is C14-C18 alkynyl.
  • In one embodiment, R1 is aryl.
  • In one embodiment, X is a covalent bond.
  • In one embodiment, X is a methylene that is optionally substituted with a hydroxyl, C1-C20 alkyl, —O—(C1-C20 alkyl), —S—(C1-C20 alkyl), —C(O)N(C1-C20 alkyl), C2-C20 alkenyl, —O—(C2-C20 alkenyl), —S—(C2-C20 alkenyl), —C(O)N(C2-C20 alkenyl), C2-C20 alkynyl, —O—(C2-C20 alkynyl), —S—(C2-C20 alkynyl), or —C(O)N(C2-C20 alkynyl).
  • In one embodiment, X is a methylene that is optionally substituted with a hydroxyl, C1-C5 alkyl, —O—(C1-C5 alkyl), —S—(C1-C5 alkyl), —C(O)N(C1-C5 alkyl), C2-C5 alkenyl, —O—(C2-C5 alkenyl), —S—(C2-C5 alkenyl), —C(O)N(C2-C5 alkenyl), C2-C5 alkynyl, —O—(C2-C5 alkynyl), —S—(C2-C5 alkynyl), or —C(O)N(C2-C5 alkynyl).
  • In one embodiment R2, R3, and R4 are methyl.
  • In one embodiment, J is —CH2CH2—.
  • In one embodiment of Formula III,
      • Y is —NHC(O)—;
      • R1 is —C11H23 or —C9H19;
      • X is —CH(OC2H5) or —CH(OC10H21);
      • J is —CH2CH2—; and
      • R2, R3, and R4 are each methyl.
    5.2.4 COMPOUNDS OF FORMULA IV
  • The compounds used in the methods of the invention also include compounds of Fonmula IV:
    Figure US20050187191A1-20050825-C00015
    and pharmaceutically acceptable salts or prodrugs thereof,
      • wherein:
      • R1 is a C6-C18 alkyl, C6-C18 alkenyl , or C6-C18 alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino, or aryl;
  • X is s-NHC(O)—, —N(CH3)C(O)—, —C(O)NH—, —C(O)N(CH3)—, —S—, —S(O)—, —(SO2)—, —O—, —NH—, or —N(CH3)—;
      • R2 is a C1-C14 alkyl, C2-C14 alkenyl, or C2-C14 alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino, or aryl;
      • Y is —NHC(O)—, —N(CH3)C(O)—, —C(O)NH—, —C(O)N(CH3)—, —S—, —S(O)—, —(SO2)—, —O—, —NH—, —N(CH3)—, or —OC(O)—;
      • R6 is a C2-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl; and
      • R3, R4, and R5 are independently methyl or ethyl, or R3 and R4 together form an aliphatic or heterocyclic ring having five or six ring atoms and R5 is methyl or ethyl.
  • In one embodiment, R1 is a C6-C18 alkyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • In one embodiment, R1 is a C6 to C18 alkenyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • In one embodiment, R1 is a C6-C18 alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • In one embodiment, R1 is aryl.
  • In one embodiment, X is —NHC(O)—.
  • In one embodiment, X is —N(CH3)C(O)—.
  • In one embodiment, X is —C(O)NH—.
  • In one embodiment, X is —C(O)N(CH3)—.
  • In one embodiment, X is —S—.
  • In one embodiment, X is —S(O)—.
  • In one embodiment, X is —(SO2)—.
  • In one embodiment, X is —O—.
  • In one embodiment, X is —NH—.
  • In one embodiment, X is —N(CH3)—.
  • In one embodiment, R2 is a C1-C14 alkyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • In one embodiment, R2 is a C2-C14 alkenyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • In one embodiment, R2 is a C2-C14 alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • In one embodiment, R2 is a C1-C5 alkyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • In one embodiment, R2 is a C2-C5 alkenyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • In one embodiment, R2 is a C2-C5 alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino.
  • In one embodiment, R2 is aryl.
  • In one embodiment, Y is —NHC(O)—.
  • In one embodiment, Y is —N(CH3)C(O)—.
  • In one embodiment, Y is —C(O)NH—.
  • In one embodiment, Y is —C(O)N(CH3)—.
  • In one embodiment, Y is —S—.
  • In one embodiment, Y is —S(O)—.
  • In one embodiment, Y is —(SO2)—.
  • In one embodiment, Y is —O—.
  • In one embodiment, Y is —NH—.
  • In one embodiment, Y is —N(CH3)—.
  • In one embodiment, Y is —OC(O)—.
  • In one embodiment, R6 is a C2-C6 alkyl.
  • In one embodiment, R6 is a C2-C6 alkenyl.
  • In one embodiment, R6 is a C2-C6 alkynyl.
  • In one embodiment, R3, R4, and R5 are methyl.
  • In one embodiment, R3, R4, and R5 are ethyl.
  • In one embodiment, R3 and R4, together form an aliphatic or heterocyclic ring having five or six ring atoms and R5 is methyl or ethyl.
  • In one embodiment of Formula IV,
      • X is —NHC(O)—;
      • R1 is —C11C23 or —C9H19;
      • Y is —O—;
      • R2 is —C2H5 or —C10H21;
      • R6 is —CH2CH2—; and
      • R3, R4, and R5 are each methyl.
  • Exemplary compounds of formula I-IV useful in the methods of the invention include, but are not limited to,
    Figure US20050187191A1-20050825-C00016
    3-dodecanamido-2-ethoxypropyl-1-phosphocholine,
    Figure US20050187191A1-20050825-C00017
    3-decanamido-2-ethoxypropyl-1-phosphocholine,
    Figure US20050187191A1-20050825-C00018
    3-decanamido-2-decyloxypropyl-1-phosphocholine,
    Figure US20050187191A1-20050825-C00019
    3-dodecanamido-2-octyloxypropyl-1-phosphocholine,
    Figure US20050187191A1-20050825-C00020
    3-dodecanamido-2-dodecyloxypropyl-1-phosphocholine, or
    Figure US20050187191A1-20050825-C00021
    3-dodecanamido-2-butyloxy-1-phosphocholine; or a combination thereof.
    • 5.2.5 COMPOUNDS OF FORMULA AA
  • The compounds used in the methods of the invention also include compounds of Formula AA:
    Figure US20050187191A1-20050825-C00022
    and pharmaceutically acceptable salts or prodrugs thereof,
      • wherein:
      • R1 is an alkyl, alkenyl, or alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino;
      • R2 is an alkyl, alkenyl, or alkynyl that is optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R″, —C(O)N(R′)(R″), —COOH, or —COOR′;
      • X1 and X2 are each selected independently from the group consisting of —N(R′)—N(R″)—, —NHC(O)—, —N(R′)C(O)—, —N(CH3)C(O)—, —C(O)NH—, —C(O)N(R′)—, —C(O)N(CH3)—, —NH—, —N(R′)—, —N(CH3)—, —(C═NH)—, —(C═NR′)—, —O(C═NH)—, —O(C═NR′)—, —(C═NH)O—, —(C═NR′)O—, —S(C═NH)—, —S(C═NR′)—, —(C═NH)S—, —(C═NR′)S—, —O(C═NH)O—, —S(C═NH)O—, —O(C═NH)S—, —S(C═NH)S—, —O(C═NR′)O—, —S(C═NR′)O—, —O(C═NR′)S—, —S(C═NR′)S—, —C(O)—, —OC(O)—, —C(O)O—, —OC(O)O—, —SC(O)—, —C(O)S—, —SC(O)O—, —OC(O)S—, —SC(O)S—, —NHC(O)NH—, —NHC(O)N(R′)—, —N(R′)C(O)NH—, —N(R′)C(O)N(R″)—, —NHC(S)—, —NR′C(S)—, —N(CH3)C(S)—, —C(S)NH—, —C(S)N(R′)—, —C(S)N(CH3)—, —C(S)—, —OC(S)—, —C(S)O—, —OC(S)O—, —SC(S)—, —C(S)S—, —SC(S)O—, —OC(O)S—, —SC(S)S—, —NHC(S)NH—, —NHC(S)N(R′)—, —N(R′)C(S)NH—, —N(R′)C(S)N(R″)—, —O—, —S—, —S(O)—, —(SO2);
      • Y1 and Y2 are selected independently from the group consisting of —O—, —S— and —Se—;
      • Z is —O—, —S—, —Se—, —NH—, or —N(R′)—;
      • W is —O—, —S—, —NH—, or —N(R′)—;
      • R6 is alkyl, alkenyl, or alkynyl.
      • R3, R4, and R5 are each independently an alkyl group, or R3 and R4 together form a heterocyclic ring having between three and seven ring atoms and R5 is an alkyl group; and
      • R′ and R″ are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocylic.
  • In one embodiment, X1 is —NHC(O)—.
  • In one embodiment, X1 is —N(CH3)C(O)—.
  • In one embodiment, X1 is —C(O)NH—.
  • In one embodiment, X1 is —C(O)N(CH3)—.
  • In one embodiment, X1 is —NH—
  • In one embodiment, X1 is —N(CH3)—.
  • In one embodiment, X2 is —NHC(O)—.
  • In one embodiment, X2 is —N(CH3)C(O)—.
  • In one embodiment, X2 is —C(O)N(CH3)—.
  • In one embodiment, X2 is —S—.
  • In one embodiment, X2 is —S(O)—.
  • In one embodiment, X2 is —(SO2)—.
  • In one embodiment, X2 is —O—.
  • In one embodiment, X2 is —NH—.
  • In one embodiment, X2 is —N(CH3)—.
  • In one embodiment, Y1 is —(O)—.
  • In one embodiment, Y1 is —S—.
  • In one embodiment, Y1 is —Se—.
  • In one embodiment, Y2 is —O—.
  • In one embodiment, Y2 is —S—.
  • In one embodiment, Y2 is —Se—.
  • In one embodiment, Z is —O—.
  • In one embodiment, Z is —S—.
  • In one embodiment, Z is —Se—.
  • In one embodiment, Z is —NH—.
  • In one embodiment, Z is —NR—.
  • In one embodiment, W is —O—.
  • In one embodiment, W is —S—.
  • In one embodiment, W is —NH—.
  • In one embodiment, W is —NR′—.
  • In one embodiment, R1 is a C1-C22 alkyl optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, R1 is a C1-C12 alkyl optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, R1 a C2-C22 alkenyl optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, R1 is a C2-C12 alkenyl optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, R1 a C2-C22 alkynyl optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, R1 is a C2-C12 alkynyl optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, R2 a C1-C22 alkyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R″, —C(O)N(R′)(R″), —COOH, or —COOR′.
  • In one embodiment, R2 is a C1-C12 alkyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R″, —C(O)N(R′)(R″), —COOH, or —COOR′.
  • In one embodiment, R2 a C1-C5 alkyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R″, —C(O)N(R′)(R″), —COOH, or —COOR′.
  • In one embodiment, R2 is a C2-C22 alkenyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R″, —C(O)N(R′)(R″), —COOH, or —COOR′.
  • In one embodiment, R2 is a C2-C12 alkenyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R″, —C(O)N(R′)(R″), —COOH, or —COOR′.
  • In one embodiment, R2 is a C2-C5 alkenyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R″, —C(O)N(R′)(R″), —COOH, or —COOR′.
  • In one embodiment, R2 is a C2-C22 alkynyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R″, —C(O)N(R′)(R″), —COOH, or —COOR′.
  • In one embodiment, R2 is a C2-C12 alkynyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R″, —C(O)N(R′)(R″), —COOH, or —COOR′.
  • In one embodiment, R2 is a C2-C5 alkynyl optionally substituted from 1 to 5 times with —OH, —SH, oxo, amino, —N(R′)C(O)R″, —C(O)N(R′)(R″), —COOH, or —COOR′.
  • In one embodiment, R6 is a C2-C6 alkyl.
  • In one embodiment, R6 is —CH2—.
  • In one embodiment, R6 is —CH2—CH2—.
  • In one embodiment, R6 is a C2-C6 alkenyl.
  • In one embodiment, R6 is a C2-C6 alkynyl.
  • In one embodiment, R3, R4, and R5 are each independently a C1-C6 alkyl.
  • In one embodiment, each R3, R4 and R5 is independently a methyl or ethyl.
  • In one embodiment, R3 and R4 together form a heterocyclic ring having between three and seven ring atoms and R5 is an alkyl group.
  • In one embodiment, R3 and R4 together form a heterocyclic ring having between three and seven ring atoms and R5 is methyl.
  • In one embodiment, R3 and R4 together form a heterocyclic ring having between three and seven ring atoms and R5 is ethyl.
  • In one embodiment, each R′ and R″ is independently a C1-C22 alkyl group.
  • In one embodiment, compounds useful in the methods of the invention include compounds of Formula AA-1:
    Figure US20050187191A1-20050825-C00023
    and pharmaceutically acceptable salts or prodrugs thereof,
      • wherein:
      • R1 is an C1-C12 alkyl, C2-C12 alkenyl, or C2-C12 alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino;
      • X1 is —NHC(O)—, —N(CH3)C(O)—, —C(O)NH—, —C(O)N(CH3)—, —NH— or —N(CH3)—;
      • R2 is C1-C12 alkyl, C2-C12 alkenyl, or C2-C12 alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino;
      • X2 is —NHC(O)—, —N(CH3)C(O)—, —C(O)N(CH3)—, —S—, —S(O)—, —(SO2)—, —O—, —NH—, or —N(CH3)—;
      • R6 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl; and
      • R3, R4, and R5 are each independently methyl or ethyl, or R3 and R4 together form a heterocyclic ring having five or six ring atoms and R5 is methyl or ethyl.
  • In one embodiment, R1 is a C1-C12 alkyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, R1 is a C2-C12 alkenyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, R1 is a C2-C12 alkynyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, R1 is a C1-C5 alkyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, R1 is a C2-C5 alkenyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, R1 is a C2-C5 alkynyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, X1 is —NHC(O)—.
  • In one embodiment, X1 is —N(CH3)C(O)—.
  • In one embodiment, X1 is —C(O)NH—.
  • In one embodiment, X1 is —C(O)N(CH3)—.
  • In one embodiment, X1 is —NH—.
  • In one embodiment, X1 is —N(CH3)—.
  • In one embodiment, R2 is a C1-C12 alkyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, R is a C2-C12 alkenyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, R2 is a C2-C12 alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, R is a C1-C5 alkyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, R is a C2-C5 alkenyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, R is a C2-C5 alkynyl substituted from 1 to 5 times with —OH, —COOH, oxo, or amino.
  • In one embodiment, X2 is —NHC(O)—.
  • In one embodiment, X2 is —N(CH3)C(O)—
  • In one embodiment, X2 is —C(O)N(CH3)—.
  • In one embodiment, X2 is —S—.
  • In one embodiment, X2 is —S(O)—.
  • In one embodiment, X2 is —(SO2)—.
  • In one embodiment, X2 is —O—.
  • In one embodiment, X2is —NH—.
  • In one embodiment, X2 is —N(CH3)—.
  • In one embodiment, R6 is a C2-C6 alkyl.
  • In one embodiment, R6 is a C2-C6 alkenyl.
  • In one embodiment, R6 is a C2-C6 alkynyl.
  • In one embodiment, each R3, R4, and R5 is independently methyl or ethyl.
  • In one embodiment, R3 and R4 together form a heterocyclic ring having five or six ring atoms and R5 is methyl.
  • In one embodiment, R3 and R4 together form a heterocyclic ring having five or six ring atoms and R5 is ethyl.
  • In one embodiment, compounds useful in the methods of the invention include compounds of Formula AA-1:
    Figure US20050187191A1-20050825-C00024
    and pharmaceutically acceptable salts or prodrugs thereof,
      • wherein:
      • X1 is —NHC(O)—, —N(CH3)C(O)—, —C(O)NH—, —C(O)N(CH3)—, —NH— or —N(CH3)—;
      • X2 is —NHC(O)—, —N(CH3)C(O)—, —C(O)N(CH3)—, —S—, —S(O)—, —(SO2)—, —O—, —NH—, or —N(CH3)—;
      • R1 is an C1-C22 alkyl, C2-C22 alkenyl, or C2-C22 alkynyl;
      • R2 is an C1-C12 alkyl, C2-C12 alkenyl, or C2-C12 alkynyl;
        and at least one of R1 or R2 is a C1-C7 alkyl, C2-C7 alkenyl, or C2-C7 alkynyl;
      • R6 is a C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl; and
      • R3, R4, and R5 are each independently methyl or ethyl or R3 and R4 together form a heterocyclic ring having five or six ring atoms and R5 is methyl or ethyl.
  • In one embodiment, one or more alkyl groups is substituted.
  • In one embodiment, X1 is —NHC(O)—.
  • In one embodiment, X1 is —N(CH3)C(O)—.
  • In one embodiment, X1 is —C(O)NH—.
  • In one embodiment, X1 is —C(O)N(CH3)—.
  • In one embodiment, X1 is —NH—.
  • In one embodiment, X1 is —N(CH3)—.
  • In one embodiment, X2 is —NHC(O)—.
  • In one embodiment, X2 is —N(CH3)C(O)—
  • In one embodiment, X2 is —C(O)N(CH3)—.
  • In one embodiment, X2 is —S—.
  • In one embodiment, X2 is —S(O)N.
  • In one embodiment, X2 is —(SO2)—.
  • In one embodiment, X2 is —O—.
  • In one embodiment, X2 is —NH—.
  • In one embodiment, X2 is —(NCH3)—
  • In one embodiment, R1 is a C1-C12 alkyl.
  • In one embodiment, R1 is a C2-C12 alkenyl.
  • In one embodiment, R1 is a C2-C12 alkynyl.
  • In one embodiment, R2 is a C1-C12 alky
  • In one embodiment, R2 is a C2-C12 alkenyl.
  • In one embodiment, R2 is a C2-C12 alkynyl.
  • In one embodiment, at least one of R1 or R2 is a C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl.
  • In one embodiment, at least one of R1 or R2 is a C1-C3 alkyl.
  • In one embodiment, at least one of R1 or R2 is a C2-C3 alkenyl.
  • In one embodiment, at least one of R1 or R2 is a C2-C3 alkynyl group.
  • In one embodiment, R2 is a C1-C5 alkyl.
  • In one embodiment, R2 is a C2-C5 alkenyl.
  • In one embodiment, R2 is a C2-C5 alkynyl group.
  • In one embodiment, R6 is a C2-C6 alkyl.
  • In one embodiment, R6 is a C2-C6 alkenyl.
  • In one embodiment, R6 is a C2-C6 alkynyl.
  • In one embodiment of the compound of formula AA-1,
      • X1 is —NHC(O)—;
      • X2 is —S— or —O—;
      • R1 and R2 are each a CC1-C22 straight chain alkyl and at least one of R1 or R2is a C1-C5 straight chain alkyl;
      • R6 is a C2-C6 straight chain alkyl; and
      • R3, R4, and R5 are each independently methyl or ethyl.
  • In one embodiment of the compound of formula AA-1,
      • X1 is —NHC(O)—;
      • X2 is —S— or —O—;
      • R1 and R2 are each a C1-C12 straight chain alkyl and at least one of R1 or R2is a C1-C5 straight chain alkyl;
      • R6 is a C2-C6 straight chain alkyl; and
      • R3, R4, and R5 are each independently methyl or ethyl.
  • In one embodiment of the compound of formula AA-1,
      • X1 is —NHC(O)—;
      • X2 is —S— or —O—;
      • R1 is a C1-C22 straight chain alkyl;
      • R2 is a C1-C5 straight chain alkyl;
      • R6 is —CH2CH2—; and
      • R3, R4, and R5 are each methyl.
  • In one embodiment of the compound of formula AA-1,
      • X1 is —NHC(O)—;
      • X2 is —S—or —O—;
      • R1 is a C7-C11 straight chain alkyl;
      • R2 is a C1-C5 straight chain alkyl;
      • R6 is a —CH2CH2—; and
      • R3, R4, and R5 are each methyl.
  • In one embodiment of the compound of formula AA-1,
      • X1 is —NHC(O)—;
      • X2 is —S—or —O—;
      • R1 is a C7-C11 straight chain alkyl;
      • R2 is a methyl or ethyl;
      • R6 is a —CH2CH2—; and
      • R3, R4, and R5 are each methyl.
  • In one embodiment of the compound of formula AA-1,
      • X1 is —NHC(O)—;
      • X2 is —O—;
      • R1 is —C1-C22 alkyl;
      • R2 is —C1-C22 alkyl;
      • R6 is —CH2CH2—; and
      • R3, R4 and R5 are methyl.
  • In one embodiment of the compound of formula AA-1,
      • X1 is —NHC(O)—;
      • X2 is —O—;
      • R1 is —CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, —CH2CH2CH2Ch2CH3, —(CH2)5CH3, —(CH2)6CH3, —(CH2)7CH3, —(CH2)8CH3, —(CH2)9CH3, —(CH2)10CH3, —(CH2)11CH3, —(CH2)12CH3 or —(CH2)13CH3;
      • R2 is —CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, —CH2CH2CH2CH2CH3, —(CH2)5CH3, —(CH2)6CH3, —(CH2)7CH3, —(CH2)8CH3, —(CH2)9CH3, —(CH2)10Ch3, —(CH2)11CH3, —(CH2)12CH3 or —(CH2)13CH3;
      • R6 is —CH2CH2—; and
      • R3, R4 and R5 are methyl.
  • In one embodiment of the compound of Formula AA-1,
      • X1 is —NHC(O)—;
      • X2 is —O—;
      • R1 —(CH 2)8CH3, —(CH2)9CH3, —(CH2)10CH3, —(CH2)11CH3; —(CH2)12CH3, or —(CH2)13CH3;
      • R2is CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, —CH2CH2Ch2CH2CH3, —(CH2)5CH3, —(CH2)6CH3, or —(CH2)7CH3;
      • R6 is —CH2CH2—; and
      • R3, R4 and R5 are methyl.
  • In one embodiment of the compound of Formula AA-1,
      • X1 is —NHC(O)—;
      • X2 is —O—;
      • R1 is —(CH2)5CH3, —(CH2)6CH3, —(CH2)7CH3, —(CH2)8CH3, —(CH2)9CH3, —(CH2)10CH3, —(CH2)11CH3, or —(CH2)12CH3;
      • R2 is —(CH2)6CH3, —(CH2)7CH3, —(CH2)8CH3, —(CH2)9CH3, —(CH2)1CH3, —(CH2)11CH3, —(CH2)12CH3, or —(CH2)13CH3;
      • R6 is —CH2CH2—; and
      • R3, R4 and R5 are methyl.
    5.2.6 COMPOUNDS OF FORMULA BB
  • The compounds used in the methods of the invention also include compounds of Formula BB-1:
    Figure US20050187191A1-20050825-C00025
    and pharmaceutically acceptable salts or prodrugs thereof.
  • The compounds used in the methods of the invention also include compounds of Formula BB-2:
    Figure US20050187191A1-20050825-C00026
    and pharmaceutically acceptable salts or prodrugs thereof.
  • The compounds used in the methods of the invention also include compounds of Formula BB-3:
    Figure US20050187191A1-20050825-C00027
    and pharmaceutically acceptable salts or prodrugs thereof.
  • The compounds used in the methods of the invention also include compounds of Formula BB-4:
    Figure US20050187191A1-20050825-C00028
    and pharmaceutically acceptable salts or prodrugs thereof.
    • 5.2.7 OTHER COMPOUNDS USEFUL IN THE METHODS OF THE INVENTION
  • The compounds used in the methods of the invention also include the phospholipids compounds disclosed in PCT publication WO 91/09602 (Boehringer Mannheim), which is incorporated herein in its entirety, and in particular phospholipids of the formula:
    Figure US20050187191A1-20050825-C00029
    and pharmaceutically acceptable salts or prodrugs thereof,
      • wherein:
      • R1 is a straight-chain or branched, saturated or unsaturated aliphatic residue, in particular an alkyl residue, with 9 to 30 carbon atoms, which can also be part of a C5-C7 cycloalkane ring and may be substituted with one or more hydroxy, halogen, nitrile, a C5-C7 cycloalkyl, phenyl, C1-C20 alkoxy carbonyl, C1-C20 alkyl carbonyl, C1-C20 alkyl carbamoyl, C1-C20 alkyl mercapto, C1-C20 alkane sulphinyl, C1-C20 alkane sulphonyl, C1-C20 acyl amino groups or by C1-C20 alkoxy which in turn can be substituted by phenyl, C1-C20 alkyl mercapto, C1-C20 alkane sulphinyl, C1-C20 alkane sulphonyl, C1-C20 acyl amino, C1-C20 alkoxy carbonyl, nitrile, hydroxy, C1-C20 alkoxy or C1-C20 alkyl carbamoyl;
      • R2 is a straight-chain or branched alkylene chain with 2 to 6, preferably 2 to 4, carbon atoms;
      • R3 is hydrogen or a C1-C6 alkyl group; and
  • Y is an oxygen or a sulphur atom.
  • The compounds used in the methods of the invention also include the phospholipid compounds disclosed in WO 91/05558 (Boehringer Mannheim), which is incorporated herein in its entirety, and in particular phospholipids of the formula:
    Figure US20050187191A1-20050825-C00030
    and pharmaceutically acceptable salts or prodrug thereof,
      • wherein:
      • X is a valence bond, an oxygen atom or sulphur atom, a sulphinyl, sulphonyl, carbonyl, aminocarbonyl, carbonylamino or ureido (—NH—CO—NH—) group or a C3-C8 cycloalkylene or phenylene residue;
      • Y is an oxygen atom or the groups —O—CO—O—, —O—CO—NH—, —O—CS—NH—;
      • R1 is a hydrogen atom, a straight-chain or branched, saturated or unsaturated alkyl residue with 1-18 or 2-18 carbon atoms, respectively, which may be substituted one or more times by phenyl, halogen, C1-C4 alkoxy, C1-C4 alkylmercapto, C1-C4 alkoxycarbonyl, C1-C4 alkane sulphinyl or C1-C4 alkane sulphonyl groups,
      • R2 is a straight or branched, saturated or unsaturated alkylene chain with 1-18 or 2-18 carbon atoms, respectively, which may be substituted one or more times by halogen, phenyl, C1-C4 alkoxy, C1-C4 alkoxycarbonyl, C1-C4 alkylmercapto, C1-C4 alkane sulphinyl or C1-C4 alkane sulphonyl groups;
      • R3is a straight or branched, saturated or unsaturated alkylene chain with 2-8 carbon atoms which can also be substituted;
      • R4is a straight or branched alkylene chain with 2-5 carbon atoms;
      • R5 is hydrogen or a C1-C6 alkyl group; and
      • Z is oxygen or sulphur.
  • The compounds used in the methods of the invention also include the phospholipid compounds disclosed in U.S. Pat. No. 4,444,766 (Boehringer Mannheim), which is incorporated herein in its entirety, and in particular phospholipids of the formula:
    Figure US20050187191A1-20050825-C00031
    and pharmaceutically acceptable salts or prodrug thereof,
      • wherein:
      • X is a valency bond, an oxygen or sulphur atom, a sulphonyl or sulphonyl group, an aminocarbonyl, carbonylamino or ureido group or a cycloalkylene radical or a phenylene radical;
      • Y is an oxygen or sulphur atom;
      • R1 is a hydrogen atom, a straight-chained or branched, saturated or unsaturated aliphatic hydrocarbon radical containing up to 18 carbon atoms, which is optionally substituted one or more times by aryl, halogen, lower alkoxy, alkylthio, alkoxycarbonyl, alkanesulphinyl or alkanesulphonyl;
      • R2 is a straight-chained or branched, saturated or unsaturated aliphatic hydrocarbon chain containing up to 18 carbon atoms, which is optionally substituted one or more times by halogen, aryl, lower alkoxy, alkoxycarbonyl, alkylthio, alkanesulphinyl or alkanesulphonyl,
      • R3 is a straight-chained or branched, saturated or unsaturated aliphatic hydrocarbon chain containing 2 to 8 carbon atoms, which can also be part of a cycloalkane ring and which is optionally substituted one or more times by hydroxy, halogen, nitrile, cycloalkyl, phenyl, alkoxycarbonyl, optionally alkylated carbamoyl, alkylthio, alkanesulphinyl, alkanesulphonyl, optionally acylated amino or by alkoxy which, in turn, can be substituted by aryl, alkylthio, alkanesulphinyl, alkanesulphonyl, optionally acylated amino, alkoxycarbonyl, nitrile, hydroxyl, alkoxy or optionally alkylated carbamoyl;
      • R4 is a straight-chained or branched alkylene chain containing 2 to 4 carbon atoms;
      • R5 is a hydrogen atom or a lower,alkyl radical;
      • and n is 0, 1 or 2
  • In addition, exemplary compounds include any of the compounds disclosed in Ouyang et al., Journal of Medicinal Chemistry 45:2857-2866 (2002), the disclosure of which is hereby incorporated by reference. Other compounds that may be used, alone or in combination, for the treatment of RSV, as disclosed herein, include compounds disclosed in U.S. Pat. No. 5,614,548, U.S. Pat. No. 5,962,437, and U.S. Pat. No. 5,770,584, the disclosures of which are hereby incorporated by reference.
  • The invention also provides the use of a compound of the invention, optionally with a pharmaceutical acceptable carrier or diluent, for the manufacture of a medicament for the treatment of a host infected with RSV.
    • 5.3 METHODS OF SYNTHESIS OF COMPOUNDS
  • Methods for obtaining the compounds of the invention are well known to those skilled in the art. Alkylamidophosphocholines may be prepared according to the method disclosed in Ouyang et al., Journal of Medicinal Chemistry 45(13): 2857-2866 (2002), and as described in Example 3 and FIG. 1. 3-Alkylamido-2-alkoxypropylphosphocholine is obtained by reacting commercially available 3-amino-1,2-propanediol with the appropriate acid chloride or anhydride. The primary alcohol is protected, and the secondary alcohol is alkylated with an alkyl bromide. The primary alcohol is deprotected, and then reacted with 2-bromoethyl dichiorophosphate and trimethylamine, to obtain the 3-alkylamido-2-alkoxypropylphosphocholine compound.
  • The compounds of the invention can also be prepared using the methods disclosed in Morris-Natschke S L, Gumus F, Marasco C J, Meyer K L, Marx M, Piantadosi, Layne M D, Modest E J, “Synthesis of Phosphocholine and Quaternary Amine Ether Lipids and Evaluation of In Vitro Antineoplastic Activity,” Journal of Medicinal Chemistry, 36:2018-2025 (1993); Piantadosi C., Marasco C. J., Morris-Natschke S. L., Meyer K. L., Gumus F., Surles J. R., Ishaq K. S., ” Synthesis and Evaluation of Novel Ether Lipid Nucleoside Conjugates for Anti-HIV-1 Activity,” Journal of Medicinal Chemistry, 34:1408-1414 (1991); Kucera L. S., Morris-Natschke S. L., Ishaq K. S., Hes J., Iyer N., Furman P. A., Fleming R. A., ” Synthesis and Evaluation of a Novel Synthetic Phosphocholine Lipid-AZT Conjugate that Double-Targets Wild-type and Drug Resistant Variants of HIV,” Nucleosides, Nucleotides, and Nucleic Acids, 23:385-399 (2004); Meyer K. L., Marasco C. J., Morris-Natschke S. L., Ishaq K. S., Piantadosi C., Kucera L. S.,” In Vitro Evaluation of Phosphocholine and Quaternary Ammonium Containing Lipids as Novel Anti-HIV Agents,” Journal of Medicinal Chemistry, 34:1377-1383 (1991); and Morris-Natschke S. L., Surles J. R., Daniel L. W., Berens M. E., Modest E. J., Piantadosi C., ” Synthesis of Sulfur analogues of Alkyl Lysophospholipid and Neoplastic Cell Growth Inhibitory Properties,” Journal of Medicinal Chemistry, 29:2114-2117 (1986).
  • Other compounds which may be used, alone or in combination, for the treatment of RSV, as disclosed herein, and the synthesis thereof, are disclosed in U.S. Pat. No. 5,614,548, U.S. Pat. No. 5,962,437, and U.S. Pat. No. 5,770,584, which are hereby incorporated by reference.
    • 5.4 PREPARATION AND ADMINISTRATION OF COMPOUNDS
  • The compounds of the invention may be prepared in the form of a pharmaceutically acceptable salt or a non-pharmaceutically acceptable salt. Non-pharmaceutically acceptable salts are useful, for example, as intermediates for preparation of a pharmaceutically acceptable salt. When the compounds are sufficiently basic or acidic to form stable non-toxic acid or base salts, the compounds may be prepared as a pharmaceutically acceptable salt. Pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound and do not impart undesirable toxicological effects.
  • Examples of such salts are acid addition salts formed with inorganic acids, for example, hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids and the like; salts formed with organic acids such as acetic, oxalic, tartaric, succinic, maleic, fumaric, gluconic, citric, malic, methanesulfonic, p-toluenesulfonic, napthalenesulfonic, and polygalacturonic acids, and the like; salts formed from elemental anions such as chloride, bromide, and iodide; salts formed from metal hydroxides, for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, and magnesium hydroxide; salts formed from metal carbonates, for example, sodium carbonate, potassium carbonate, calcium carbonate, and magnesium carbonate; salts formed from metal bicarbonates, for example, sodium bicarbonate and potassium bicarbonate; salts formed from metal sulfates, for example, sodium sulfate and potassium sulfate; and salts formed from metal nitrates, for example, sodium nitrate and potassium nitrate.
  • Pharmaceutically acceptable and non-pharmaceutically acceptable salts may be prepared using procedures well known in the art, for example, by reacting a sufficiently basic compound such as an amine with a suitable acid comprising a physiologically acceptable anion. Alkali metal (for example, sodium, potassium, or lithium) or alkaline earth metal (for example, calcium) salts of carboxylic acids can also be made.
  • The compounds of the invention may be formulated as pharmaceutical compositions and administered to a host, such as a human patient, by a chosen route of administration. Pharmaceutical compositions that are useful in the methods of the invention can be prepared, packaged, or sold in a variety of formulations which can be suitable for one or more routes of administration such as, for example, oral, intravenous, intramuscular, topical, subcutaneous, rectal, vaginal, parenteral, pulmonary, intranasal, buccal, ophthalmic, or another route of administration. The active materials can be administered in liquid or solid form. Other contemplated formulations include projected nanoparticles, liposomal preparations, resealed erythrocytes containing the active ingredient, and immunologically-based formulations.
  • Although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for ethical administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to hosts of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and perform such modification with merely ordinary, if any, experimentation. Subjects to which administration of the pharmaceutical compositions of the invention is contemplated include, but are not limited to, humans and other primates and mammals including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, and dogs.
  • Thus, the compounds of the invention may be systemically administered (e.g. orally) in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They can be enclosed in hard or soft shell gelatin capsules, compressed into tablets, or incorporated directly into the food of the patient's diet. For oral therapeutic administration, the active compound can be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • The concentration of active compound in the drug composition will depend on absorption, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time. Pharmaceutically compatible binding agents, and/or adjuvant materials may also be included as part of the composition.
  • Such compositions and preparations should contain at least 0.1% (w/w) of active compound. The percentage of the compositions and preparations can, of course, be varied, for example from about 0.1% to nearly 100% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained upon administration.
  • The tablets, froches, pills, capsules, and the like may also contain one or more of the following: binders, such as microcrystalline cellulose, gum tragacanth, acacia, corn starch, or gelatin; excipients, such as dicalcium phosphate, starch or lactose; a disintegrating agent, such as corn starch, potato starch, alginic acid, primogel, and the like; a lubricant, such as magnesium stearate or Sterotes; a glidant, such as colloidal silicon dixoide; a sweetening agent, such as sucrose, fructose, lactose, saccharin, or aspartame; a flavoring agent such as peppermint, methylsalicylate, oil of wintergreen, or cherry flavoring; and a peptide antiviral agent, such as envuvirtide (Fuzeon™). When the unit dosage form is a capsule, it can contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules can be coated with gelatin, wax, shellac, sugar, and the like. A syrup or elixir can contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye, and flavoring such as cherry or orange flavor. Of course, any material used in preparing a unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.
  • The compounds of the invention thereof may also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, antiinflammatories, protease inhibitors, or other nucleoside or nonnucleoside antiviral agents. Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application may include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation may be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers may be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylacetic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials may also be obtained commercially from Alza Corporation.
  • The active compound may be administered orally, intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts may be prepared in water, optionally mixed with a non-toxic surfactant. Dispersions may be prepared in glycerol, liquid polyethylene glycols, triacetin, mixtures thereof, and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent growth of microorganisms.
  • Pharmaceutical dosage forms suitable for injection or infusion may include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. The ultimate dosage form should be sterile, fluid, and stable under conditions of manufacture and storage. The liquid carrier or vehicle may be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity may be maintained, for example, by formation of liposomes, by the maintenance of the required particle size (in the case of dispersions) or by use of one or more surfactants. Microbial growth may be prevented using various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers, or sodium chloride. Prolonged absorption of the injectable compositions may be achieved using agents which delay absorption, for example, aluminum monostearate and gelatin.
  • Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) are also preferred as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811. For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
  • Sterile injectable solutions are prepared by incorporating the active compound in the required amount in an appropriate solvent, optionally with one or more of the other ingredients enumerated above, followed by filter sterilization. In the case of sterile powders for preparation of sterile injectable solutions, preferred methods of preparation include vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient and any additional desired ingredient present in the previously-sterile-filtered solution(s).
  • A pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for rectal administration. Such a composition may be in the form of, for example, a suppository, a retention enema preparation, and a solution for rectal or colonic irrigation.
  • Suppository formulations may be made by combining the active ingredient with a non-irritating pharmaceutically acceptable excipient which is solid at ordinary room temperature (i.e. about 20° C.) and which is liquid at the rectal temperature of the subject (i.e. about 37° C. in a healthy human). Suitable pharmaceutically acceptable excipients include, but are not limited to, cocoa butter, polyethylene glycols, and various glycerides. Suppository formulations may further comprise various additional ingredients including, but not limited to, antioxidants and preservatives.
  • Retention enema preparations or solutions for rectal or colonic irrigation may be made by combining the active ingredient with a pharmaceutically acceptable liquid carrier. As is well known in the art, enema preparations may be administered using, and may be packaged within, a delivery device adapted to the rectal anatomy of the subject. Enema preparations may further comprise various additional ingredients including, but not limited to, antioxidants and preservatives.
  • A pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for vaginal administration. Such a composition may be in the form of, for example, a suppository, an impregnated or coated vaginally-insertable material such as a tampon, a douche preparation, or a solution for vaginal irrigation.
  • Methods for impregnating or coating a material with a chemical composition are known in the art, and include, but are not limited to, methods of depositing or binding a chemical composition onto a surface, methods of incorporating a chemical composition into the structure of a material during the synthesis of the material (i.e. such as with a physiologically degradable material), and methods of absorbing an aqueous or oily solution or suspension into an absorbent material, with or without subsequent drying.
  • Douche preparations or solutions for vaginal irrigation may be made by combining the active ingredient with a pharmaceutically acceptable liquid carrier. As is well known in the art, douche preparations may be administered using, and may be packaged within, a delivery device adapted to the vaginal anatomy of the subject. Douche preparations may further comprise various additional ingredients including, but not limited to, antioxidants, antibiotics, antifungal agents, and preservatives.
  • A pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for pulmonary administration via the buccal cavity. Such a formulation may comprise dry particles which comprise the active ingredient and which have a diameter in the range from about 0.5 to about 7 nanometers, and preferably from about 1 to about 6 nanometers. Such compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant may be directed to disperse the powder or using a self-propelling solvent/powder-dispensing container such as a device comprising the active ingredient dissolved or suspended in a low-boiling propellant in a sealed container. Preferably, such powders comprise particles wherein at least 98% of the particles by weight have a diameter greater than 0.5 nanometers and at least 95% of the particles by number have a diameter less than 7 nanometers. More preferably, at least 95% of the particles by weight have a diameter greater than 1 nanometer and at least 90% of the particles by number have a diameter less than 6 nanometers. Dry powder compositions preferably include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.
  • Low boiling propellants generally include liquid propellants having a boiling point of below 65° F. at atmospheric pressure. Generally, the propellant may constitute 50 to 99.9% (w/w) of the composition, and the active ingredient may constitute 0.1 to 20% (w/w) of the composition. The propellant may further comprise additional ingredients such as a liquid non-ionic or solid anionic surfactant or a solid diluent (preferably having a particle size of the same order as particles comprising the active ingredient).
  • Pharmaceutical compositions of the invention formulated for pulmonary delivery may also provide the active ingredient in the form of droplets of a solution or suspension. Such formulations may be prepared, packaged, or sold as aqueous or dilute alcoholic solutions or suspensions, optionally sterile, comprising the active ingredient, and may conveniently be administered using any nebulization or atomization device. Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, or a preservative such as methylhydroxybenzoate. The droplets provided by this route of administration preferably have an average diameter in the range from about 0.1 to about 200 nanometers.
  • The formulations described herein as being useful for pulmonary delivery are also useful for intranasal delivery of a pharmaceutical composition of the invention. Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 to 500 micrometers. Such a formulation is administered in the manner in which snuff is taken i.e. by rapid inhalation through the nasal passage from a container of the powder held close to the nares.
  • Formulations suitable for nasal administration may, for example, comprise from about as little as 0.1% (w/w) and as much as 100% (w/w) of the active ingredient, and may further comprise one or more of the additional ingredients described herein.
  • A pharmaceutical composition of the invention may be prepared, packaged, or sold in a formulation suitable for ophthalmic administration. Such formulations may, for example, be in the form of eye drops including, for example, a 0.1-1.0% (w/w) solution or suspension of the active ingredient in an aqueous or oily liquid carrier. Such drops may further comprise buffering agents, salts, or one or more other of the additional ingredients described herein. Other ophthalmalmically-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form or in a liposomal preparation.
  • For topical administration, the present compounds can be applied in pure form, i.e., as a liquid. However, it will generally be desirable to administer the compounds to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
  • Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina, and the like. Useful liquid carriers include water, alcohols, glycols, and blends of two or more of these, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize properties for a given use. The resulting liquid compositions can be applied using absorbent pads, used to impregnate bandages or other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
  • Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses, or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
  • Examples of useful dermatological compositions which can be used to deliver the compounds of the invention to the skin are disclosed in Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).
  • Accordingly, the invention includes pharmaceutical compositions comprising one or more compounds of the invention or any combination thereof, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
  • In one embodiment, the pharmaceutical composition is adapted for oral, topical, or parenteral administration to a mammal, such as a human, and comprises one or more compounds of the invention, or any combination thereof, or a pharmaceutically acceptable salt thereof, in an amount effective to treat RSV.
  • As used herein, “treatment” of RSV can mean, for example, any one or more of the following: inhibiting the replication of the virus, reducing the virus load within a patient, inhibiting formation of infectious progeny virus, inhibiting infectiousness of virus, killing cells harboring virus, interfering with one or more stages of the virus life cycle, inhibiting one or more viral enzymes or inducing production of non-infectious virus particles that can activate an immune response against infectious virus (e.g. autovaccination).
  • Useful dosages of the compounds of the invention for inclusion in the pharmaceutical compositions of the invention can be determined by comparing in vitro activity and in vivo activity of the compounds in appropriate animal models. Methods for the extrapolation of effective dosages in mice and other animal models to humans are known in the art (see, for example, U.S. Pat. No. 4,938,949).
  • Generally, the concentration of the compound(s) of the invention in a liquid composition, such as a lotion, will range from about 0.1% to about 95% by weight, preferably from about 0.5 % to about 25% by weight. The concentration in a semi-solid or solid composition such as a gel or a powder will range from about 0.1% to 100% by weight, preferably about 0.5% to about 5 % by weight. Single doses for intravenous injection, subcutaneous, intramuscular or topical administration, infusion, ingestion or suppository will generally be from about 0.001 to about 5000 mg, and be administered from about 1 to about 3 times daily, to yield levels of about 0.01 to about 500 mg/kg, for adults.
  • The invention also includes one or more compounds of the invention, or any combination thereof, in an amount effective to inhibit RSV replication in a host. The compound of course is therefore useful for inhibiting virus replication in a cell or neutralization (i.e. inactivation) of extracellular virus. Additionally, the invention includes one or more compound of the invention present as a pharmaceutically acceptable salt, or any combination thereof, wherein the compound is present in an amount effective to inhibit RSV replication in a host.
  • As used herein, to inhibit RSV replication in a host means to reduce the virus load in a host to a level which is lower than the level of the virus load in an otherwise identical mammal which was not administered the compound. Preferably, virus load in a mammal is reduced by about 1 to 12 log10 or more relative to an otherwise identical mammal which was not administered the compound. Virus load in a mammal can be assessed by a number of methods known in the art such as, for example, obtaining a tissue or fluid sample from the mammal and assessing the amount of virus or viral components in the mammal contained therein using technology which is either virological, immunological, biochemical or molecular biological in nature and which is well known to the skilled artisan and which are described elsewhere herein. Inhibition of RSV replication in a cell is assessed using similar or identical assays as those used to assess virus load in a mammal.
  • The invention also includes a kit for administering a composition of the invention (e.g. a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention) to a host for treatment of RSV infection. Preferably, the host is a human. The kit comprises the composition of the invention and an instructional material, which describes adventitially administering the composition to the mammal by any of the routes of administration described herein. In another embodiment, this kit comprises a (preferably sterile) solvent suitable for dissolving or suspending the composition of the invention prior to administering the compound to the mammal.
  • As used herein, an ” instructional material” includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the composition of the invention in the kit for any one or more of the following: effecting treatment of a RSV infection in a mammal or in a cell or alleviation or treatment of the symptoms of a RSV infection in the mammal. The instructional material of the kit of the invention may, for example, be affixed to a container which contains the composition of the invention or be shipped together with a container which contains the composition. Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and the composition be used cooperatively by the recipient.
  • The invention also includes a kit for inhibition of RSV replication in a cell. The kit comprises a composition of the invention, which can be one or more compounds of the invention, or a pharmaceutical composition comprising one or more compounds of the invention or any combination thereof. The kit also includes an instructional material.
  • As used herein, inhibition of RSV replication in a cell means a reduction in RSV replication in a cell to a level lower than the level in an otherwise identical cell which was not administered the composition of the invention. Preferably, the reduction in RSV replication is by about 90 to about 99.9% relative to the otherwise identical cell which was not administered the composition of the invention. The level of RSV replication in a cell and therefore RSV load in a mammal that is also being assessed, can be assessed by any one of numerous methods known to the skilled artisan. For example, the level of RSV replication in a cell can be assessed by evaluating the number of RSV particles or amount of a viral component, such as a viral protein, a viral enzyme, or viral nucleic acid, in the cell or in fluid or debris associated with the cell. The number of infectious virus particles in a cell can be evaluated, for example, in a plaque assay. The level of a viral component such as a viral protein or enzyme in a cell can be evaluated using standard analytical techniques of protein biochemistry, such as, for example, using an activity assay for a viral enzyme, or using Western blotting or quantitative gel electrophoresis for a viral protein. Viral nucleic acid levels in a cell can be evaluated using standard analytical techniques such as Northern blotting and Southern Blotting or quantitation by polymerase chain reaction (PCR).
  • The invention includes methods for treatment of a RSV infection in a host. The methods comprise administering to the host one or more compounds of the invention, or any combination thereof, or a pharmaceutically acceptable salt thereof, in an amount effective to treat the virus infection. The compound may be administered by any of the methods described herein. Preferably, the host is a human.
  • The invention also includes methods of treating a RSV infection in a host by contacting the RSV in vitro, in vivo or ex-vivo with one or more compounds of the invention, or any combination thereof, or a pharmaceutically acceptable salt thereof, in an amount effective to treat the RSV infection (e.g. to inhibit virus replication, infectivity, life cycle processes or pathogenesis). Methods for testing the antiviral activity of a compound in-vitro are known to the skilled artisan, and are described, for example, in Kucera et al., 1990, AIDS Res. and Human Retrovir. 6:494.
  • The invention further includes methods of using one or more compounds of the invention, or any combination thereof, or a pharmaceutically acceptable salt thereof, in medical therapy (preferably for use in treating a virus infection) or for the manufacture of a medicament useful for the treatment of a virus infection.
  • The invention also includes methods of inhibiting RSV replication in a cell.
  • Any of the viral treatments described in the Background of the Invention can be used in combination or alternation with the compounds described in this specification. Nonlimiting examples include:
      • (1) an interferon and/or ribavirin (Battaglia, A. M. et al., Ann. Pharmacother. 34:487-494, 2000); Berenguer, M. et al. Antivir. Ther. 3(Suppl. 3):125-136, 1998);
      • (2) substrate-based NS3 protease inhibitors (Attwood et al., Antiviral peptide derivatives, PCT WO 98/22496, 1998; Attwood et al., Antiviral Chemistry and Chemotherapy 10.259-273, 1999; Attwood et al., Preparation and use of amino acid derivatives as anti-viral agents, German Patent Publication DE 19914474; Tung et al. Inhibitors of serine proteases, PCT WO 98/17679), including alphaketoamides and hydrazinoureas, and inhibitors that terminate in an electrophile such as a boronic acid or phosphonate. (Llinas-Brunet et al, PCT WO 99/07734).
      • (3) non-substrate-based inhibitors such as 2,4,6-trihydroxy-3-nitro-benzamide derivatives (Sudo K. et al., Biochemical and Biophysical Research Communications, 238:643-647, 1997; Sudo K. et al. Antiviral Chemistry and Chemotherapy 9:186, 1998), including RD3-4082 and RD3-4078, the former substituted on the amide with a 14 carbon chain and the latter processing a para-phenoxyphenyl group;
      • (4) thiazolidine derivatives which show relevant inhibition in a reverse-phase HPLC assay with an NS3/4A fusion protein and NS5A/5 substrate (Sudo K. et al., Antiviral Research 32:9-18, 1996), especially compound RD-1-6250, possessing a fused cinnamoyl moiety substituted with a long alkyl chain, RD4 6205 and RD4 6193;
      • (5) thiazolidines and benzanilides identified in Kakiuchi N. et al., J. FEBS Letters 421:217-220; Takeshita N. et al., Analytical Biochemistry 247:242-246, 1997;
      • (6) a phenanthrenequinone possessing activity against viral protease in a SDS-PAGE and autoradiography assay isolated from the fermentation culture broth of Streptomyces sp., Sch 68631 (Chu M. et al., Tetrahedron Letters 37:7229-7232, 1996), and Sch 351633, isolated from the fungus Penicillium griseofulvum, which demonstrates activity in a scintillation proximity assay (Chu M. et al., Bioorganic and Medicinal Chemistry Letters 9:1949-1952);
      • (7) selective NS3 inhibitors based on the macromolecule elgin c, isolated from leech (Qasim M. A. et al., iochemistry 36:1598-1607, 1997);
      • (8) antisense phosphorothioate oligodeoxynucleotides (S-ODN) complementary to sequence stretches in the 5′ non-coding region (NCR) of the virus (Alt M. et al., Hepatology 22:707-717, 1995), or nucleotides 326-348 comprising the 3′ end of the NCR and nucleotides 371-388 located in the core coding region of the IICV RNA (Alt M. et al., Archives of Virology 142:589-599, 1997; Galderisi U. et al., Journal of Cellular Physiology 181:251-257, 1999);
      • (9) inhibitors of IRES-dependent translation (Ikeda N et al., Japanese Patent Publication JP-08268890; Kai Y. et al. Prevention and treatment of viral diseases, Japanese Patent Publication JP-10101591);
      • (10) nuclease-resistant ribozymes. (Maccjak D. J. et al., Hepatology 30 Abstract 995, 1999); and
      • (11) other miscellaneous compounds including 1-amino-alkylcyclohexanes (U.S. Pat. No. 6,034,134 to Gold et al.), alkyl lipids (U.S. Pat. No. 5,922,757 to Chojkier et al.), vitamin E and other antioxidants (U.S. Pat. No. 5,922,757 to Chojkier et al.), squalene, amantadine, bile acids (U.S. Pat. No. 5,846,964 to Ozeki et al.), N-(phosphonoacetyl)-L-aspartic acid, (U.S. Pat. No. 5,830,905 to Diana et al.), benzenedicarboxamides (U.S. Pat. No. 5,633,388 to Diana et al.), polyadenylic acid derivatives (U.S. Pat. No. 5,496,546 to Wang et al.), 2′,3′-dideoxyinosine (U.S. Pat. No. 5,026,687 to Yarchoan et al.), and benzimidazoles (U.S. Pat. No. 5,891,874 to Colacino et al.); and
      • (12) PEGASYS (pegylated interferon alfa-2a) by Roche, INFERGEN (interferon alfacon-1) by InterMune, OMNIFERON (natural interferon) by Viragen, ALUFERON by Human Genome Sciences, REIF (interferon beta-la) by Ares-Serono, Omega Interferon by BioMedicine, Oral Interferon Alpha by Amarillo Biosciences, Interferon gamma-b1 by InterMune, Interleukin-10 by Schering-Plough, IP-501 by Interneuron, Merimeodi VX-497 by Vertex, AMANTADINE (Symmetrel) by Endo Las Solvay, HEPTAZYME by RPI, IDN-6556 by Idun Pharma., XTL-002 by XTL., CIVACIR by NAI, LEVOVIRIN by ICN, VIRAMIDINE by ICN, ZADAXIN (thymosin alfa-1) by Sci Clone, CEPLENE (histamine dihydrochloride) by Maxim, VX 950/LY 570310 by Vertex/Eli Lilly, ISIS 14803 by Isis Pharmaceutical/Elan, IDN-6556 by Idun Pharmaceuticals, Inc. and JTK 003 by AKROS Pharma.
  • The invention will be further understood by the following non-limiting examples. These examples are provided for the purpose of illustration only and the invention is not limited to these examples, but rather includes all variations which are evident as a result of the teaching provided herein.
    • 5.5 EXAMPLES Example 1 Anti-RSV Activity of Selected Compounds
  • The ability of the active compounds to inhibit the growth of RSV was determined using a standard plaque assay with Hep-2 cell monolayers. The cell monolayers were infected with RSV (Long strain obtained from the American Tissue Culture Catalog, Cat# VR-26). After one hour of virus attachment, the cells were overlaid with medium containing methyl cellulose with or without serial concentrations of compound (0.4-50 μM). Each concentration was tested in triplicate.
  • After 6 days of incubation, the overlay medium was aspirated and the cells fixed with absolute ethanol and stained with crystal violet to visualize RSV plaques and cell cytotoxicity using a 4× dissecting microscope. To determine the percent inhibition of RSV plaque formation, the mean number of RSV plaques in the presence of compound was divided by the number of RSV plaques in the control without added compounds. The quotient was subtracted from 1 and then multiplied by 100% to establish the % inhibition. Results from these studies are shown in Table 1.
    TABLE 1
    Anti-RSV Activity
    50% Endpoint (μM)
    Effective Conc.
    (EC50)c Toxic Conc.
    RSV Plaque (TC50)c
    Compound R1 R2 R3 Count Cell Growth SIa
    KPC-15 NHCOC11H23 OCH2CH3 PCb 2.4 μM >100 μM >42
    KPC-11 NHCOC9H19 OCH2CH3 PC 3.5 μM >100 μM >28

    aSI = Selectivity Index (TC50 Cell Growth divided by EC50 Plaque Inhibition).

    bPC = Phosphocholine [OPO3 −CH2CH2N+(CH3)3].

    cEC50 and TC50 determinations were calculated by the method of Chou et al cited by Piantadosi et al. (Piantadosi et al., 1991).

    TC50 was determined using radiolabeled thymidine incorporation.
  • As illustrated in Table 1,3-dodecylamido-2-ethoxypropylphosphocholine (KPC-15) and decylamido-2-ethoxypropylphosphocholine (KPC-11) had potent in vitro activity against RSV. The effectiveness of the compounds may be due to the chemical structure as a phosphocholine analog.
    • Example 2 Toxicity Tests
  • Cells in growth phase were treated with serial concentrations of compound for 48 hours and pulse labeled with 3H-thymidine for 6 hours. The cells were then harvested to measure total DNA synthesis in the presence or absence of the compound (Kucera et al., Antiviral Chemistry and Chemotherapy, 9: i57-i65 (1998)).
  • TC50 determinations were calculated by the method of Chou et al. Elsvier: Amsterdam, 1985, as described in Piantadosi C. et al., Journal of Medicinal Chemistry, 34: 1408-1414 (1991). The TC50 for KPC-15 and KPC-11 were unable to be determined since at the highest concentration evaluated (100 μM), 50% toxicity was not observed. Results from this study are also shown in Table 1 (above). Thus, KPC-15 and KPC-11, lacked significant toxicity in vitro with the TC50>100 μM.
    • Example 3 Preparation of Pharmaceutical Compositions
  • Alkylamidophosphocholine compounds are synthesized as described in Ouyang et al., Journal of Medicinal Chemistry, 45 :2857-2866 (2002). The 3-alkylamido-2-alkoxypropylphosphocholine is obtained by reacting commercially available 3-amino-1,2,-propanediol with the appropriate acid chloride or anhydride. The primary alcohol is protected, and the secondary alcohol is alkylated with an alkyl bromide. The primary alcohol is deprotected and then reacted with 2-bromoethyl dichlorophosphate and trimethylamine to obtain the 3-alkylamido-2-alkoxypropylphosphocholine compound.
  • 3-dodecylamido-2-ethoxypropylphosphocholine was synthesized as shown in FIG. 1, and as described in Ouyang et al. FIG. 1 describes the chemical synthesis of R, S, and racemic KPC-15 and shows there is a chiral center on the C-2 position of the three carbon backbone. 3-nonylamido-2-ethoxypropylphosphocholine also was synthesized according to this method.
  • A number of references have been cited, the entire disclosures of which are incorporated herein by reference.

Claims (39)

1. A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula I:
Figure US20050187191A1-20050825-C00032
or a pharmaceutically acceptable salt or prodrug thereof,
wherein:
R1 is selected from the group consisting of —NHC(O)Y, where Y is C1-C22 alkyl, C2-C22 alkenyl, and C2-C22 alkynyl;
R2 is selected from the group consisting of —OX, where X is C1-C22 alkyl, C2-C22 alkenyl, C2-C22 alkynyl; and
R3 is phosphocholine.
2. The method of claim 1 wherein Y and X are independently C1-C14 alkyl, C2-C14 alkenyl, or C2-C14 alkynyl.
3. The method of claim 1 wherein:
Y is —C10H21; and
X is —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, or —C10H21.
4. The method of claim 1 wherein Y is —C11H23 and X is C1-C5 alkyl.
5. The method of claim 1 wherein Y is —C9H19 and X is C9-C11 alkyl.
6. The method of claim 1, wherein the compound is
Figure US20050187191A1-20050825-C00033
3-dodecanamido-2-ethoxypropyl-1-phosphocholine,
Figure US20050187191A1-20050825-C00034
3-decanamido-2-ethoxypropyl-1-phosphocholine,
Figure US20050187191A1-20050825-C00035
3-rdecanamido-2-decyloxypropyl-1-phosphocholine,
Figure US20050187191A1-20050825-C00036
3-dodecanamido-2-octyloxypropyl-1-phosphocholine,
Figure US20050187191A1-20050825-C00037
3-dodecanamido-2-dodecyloxypropyl-1-phosphocholine, or
Figure US20050187191A1-20050825-C00038
3-dodecanamido-2-butyloxy-1-phosphocholine; or a combination thereof.
7. The method of claim 1 wherein the host is a mammal.
8. The method of claim 1 wherein the host is a human.
9. A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula II:
Figure US20050187191A1-20050825-C00039
or a pharmaceutically acceptable salt or prodrugs thereof,
wherein:
M is C2-C4 alkyl;
X1 is selected from the group consisting of —S—, —O—, —NH—, and —NHC(O)—;
R21 is selected from the group consisting of C1-C20 straight chain alkyl, C2-C20 straight chain alkylene containing not more than four double bonds, and aryl;
R22 is selected from the group consisting of C1-C20 straight chain alkyl, C2-C20 straight chain alkylene containing not more than four double bonds, and aryl; and
R23, R24, and R25 are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, and isopropyl.
10. The method of claim 9 wherein
M is —CH2CH2—;
X1 is —NHC(O)—;
R21 is selected from the group consisting of a C1-C16 straight chain alkyl and C2-C16 straight chain alkylene containing not more than one double bond;
R22 is selected from the group consisting of a C1-C16 straight chain alkyl and C2-C16 straight chain alkylene containing not more than one double bond; and
R23, R24, and R25 are each independently hydrogen or methyl.
11. The method of claim 9 wherein
R21 is selected from the group consisting of C1-C16 straight chain alkyl and C2-C16 straight chain alkylene containing not more than one double bond; and
R22 is selected from the group consisting of C1-C5 straight chain alkyl and C2-C5 straight chain alkylene containing not more than one double bond.
12. The method of claim 11 wherein R21 is C9-C12 alkyl and R22 is C1-C12 alkyl.
13. The method of claim 11 wherein R21 is C9-C12 alkyl and R22 is C1-C5 alkyl.
14. The method of claim 11 wherein R21 is C9-C12 alkyl and R22 is C8-C12 alkyl.
15. The method of claim 9 wherein the host comprises a mammal.
16. The method of claim 9 wherein the host comprises a human.
17. A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula III:
Figure US20050187191A1-20050825-C00040
or a pharmaceutically acceptable salt or prodrug thereof,
wherein:
Y is selected from the group consisting of —S—, —O—, —NH—, —N(CH3)—, —NHC(O)—, and —N(CH3)C(O)—;
R1 is selected from the group consisting of C1-C18 alkyl, C2-C18 alkenyl, C2-C18 alkynyl, and aryl;
X is a covalent bond or methylene that is optionally substituted with a hydroxyl, C1-C20 alkyl, —O—(C1-C20 alkyl), —S—(C1-C20 alkyl), —C(O)N(C1-C20 alkyl), C2-C20 alkenyl, —O—(C2-C20 alkenyl), —S—(C2-C20 alkenyl), —C(O)N(C2-C20 alkenyl), C2-C20 alkynyl, —O—(C2-C20 alkynyl), —S—(C2-C20 alkynyl), or —C(O)N(C2-C20 alkynyl);
J is a C1-C4 alkyl optionally substituted from one to three times with methyl or ethyl; and
R2, R3, and R4 are independently hydrogen or C1-C3 alkyl.
18. The method of claim 17 wherein:
Y is —NHC(O)—;
R1 is C6-C18 alkyl;
X is —C(H)(O—C1-C18 alkyl)- or —C(H)(O—C1-C18 alkenyl)-;
J is —CH2CH2—; and
R2, R3, and R4 are each methyl.
19. The method of claim 18 wherein R1 is —C11H23 and X is —C(H)(O—C1-C5 alkyl)- or —C(H)(O—C1-C5 alkenyl)-
20. The method of claim 18 wherein R1 is —C9H19 and X is —C(H)(OC2H5)—.
21. The method of claim 17 wherein R1 is —C9H19 and X is —C(H)(OC10H21)—.
22. The method of claim 17 wherein the host comprises a mammal.
23. The method of claim 17 wherein the host comprises a human.
24. A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula IV:
Figure US20050187191A1-20050825-C00041
or a pharmaceutically acceptable salt or prodrug thereof,
wherein:
R1 is selected from the group consisting of C1-C18 alkyl, C2-C18 alkenyl, and C2-C18 alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino, or aryl;
X is selected from the group consisting of —NHC(O)—, —N(CH3)C(O)—, —C(O)NH—, —C(O)N(CH3)—, —S—, —S(O)—, —(SO2)—, —O—, —NH—, and —N(CH3)—;
R2 is selected from the group consisting of C1-C14 alkyl, C2-C14 alkenyl, and C2-C14 alkynyl that is optionally substituted from 1 to 5 times with —OH, —COOH, oxo, amino, or aryl;
Y is selected from the group consisting of —NHC(O)—, —N(CH3)C(O)—, —C(O)NH—, —C(O)N(CH3)—, —S—, —S(O)—, —(SO2)—, —O—, —NH—, —N(CH3)—, and —OC(O)—;
R6 is selected from the group consisting of C2-C6 alkyl; C2-C6 alkenyl, and C2-C6 alkynyl; and
R3, R4, and R5 are independently methyl or ethyl, or R3 and R4 together form an aliphatic or heterocyclic ring having five or six ring atoms and R5 is methyl or ethyl.
25. The method of claim 24 wherein:
R2 is C1-C14 alkyl, C2-C14 alkenyl, or C2-C14 alkynyl;
R6 is —CH2CH2—; and
R3, R4, and R5 are each independently CH3.
26. The method of claim 25 wherein R2 is C1-C5 alkyl or C2-C5 alkenyl.
27. The method of claim 25 wherein R1 is C8-C12 alkyl and R2 is C1-C12 alkyl.
28. The method of claim 25 wherein R1 is C8-C12 alkyl and R2 is C1-C5 alkyl.
29. The method of claim 25 wherein R1 is C8-C12 alkyl and R2 is C8-C12 alkyl
30. The method of claim 27 wherein
X is —NHC(O), —N(CH3)C(O)—, —C(O)NH—, —C(O)N(CH3); and
Y is —O—, —NH—, or —N(CH3)—.
31. The method of claim 24 wherein the host comprises a mammal.
32. The method of claim 24 wherein the host comprises a human.
33. The method of claim 24 wherein the compound comprises:
Figure US20050187191A1-20050825-C00042
3-dodecanamido-2-ethoxypropyl-1-phosphocholine.
34. The method of claim 24 wherein the compound comprises:
Figure US20050187191A1-20050825-C00043
3-decanamido-2-ethoxypropyl-1-phosphocholine.
35. A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula AA-1:
Figure US20050187191A1-20050825-C00044
or a pharmaceutically acceptable salt or prodrug thereof,
wherein:
X1 is —NHC(O)—;
X2 is —O—;
R1 is —C1-C22 alkyl;
R2 is —C1-C22 alkyl;
R6 is —CH2CH2—; and
R3, R4, and R5 are methyl.
36. The method of claim 35, wherein
R1 is —CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, —CH2CH2CH2CH2CH3, —(CH2)5CH3, —(CH2)6CH3, —(CH2)7CH3, —(CH2)8CH3, —(CH2)9CH3, —CH2)10CH3, —(CH2)11CH3, —(CH2)12CH3 or —(CH2)13CH3; and
R2is —CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, —CH2CH2CH2CH2CH3, —(CH2)5CH3, —(CH2)6CH3, —(CH2)7CH3, —(CH2)8CH3, —(CH2)9CH3, —CH2)10CH3, —(CH2)11CH3, —(CH2)12CH3 or —(CH2)13CH3.
37. The method of claim 36, wherein
Ris —(CH 2)8CH3, —(CH2)9CH3, —(CH2)10CH3, —(CH2)11CH3; —(CH2)12CH3, or —(CH2)13CH3; and
R 2is CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, —CH2CH2CH2CH2CH3, —(CH2)5CH3, —(CH2)6CH3, or —(CH2)7CH3.
38. The method of claim 36, wherein
R1 is —(CH2)5CH3, —(CH2)6CH3, —(CH2)7CH3, —(CH2)8CH3, —(CH2)9CH3, —(CH2)10CH3, —(CH2)11CH3, or —(CH2)12CH3; and
R2 is —(CH2)6CH3, —(CH2)7CH3, —(CH2)8CH3, —(CH2)9CH3CH3, —(CH2)10CH3, —(CH2)11CH3, —(CH2)12CH3, or —(CH2)13CH3.
39. The method of claim 1, wherein the administering is orally, intravenously, parentally, intradermally, subcutaneously, topically, or by inhalation.
US10/781,894 2004-02-20 2004-02-20 Methods and compositions for the treatment of respiratory syncytial virus Abandoned US20050187191A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/781,894 US20050187191A1 (en) 2004-02-20 2004-02-20 Methods and compositions for the treatment of respiratory syncytial virus
PCT/US2005/003972 WO2005099719A2 (en) 2004-02-20 2005-02-09 Methods and compositions for the treatment of respiratory syncytial virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/781,894 US20050187191A1 (en) 2004-02-20 2004-02-20 Methods and compositions for the treatment of respiratory syncytial virus

Publications (1)

Publication Number Publication Date
US20050187191A1 true US20050187191A1 (en) 2005-08-25

Family

ID=34860950

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/781,894 Abandoned US20050187191A1 (en) 2004-02-20 2004-02-20 Methods and compositions for the treatment of respiratory syncytial virus

Country Status (2)

Country Link
US (1) US20050187191A1 (en)
WO (1) WO2005099719A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080009462A1 (en) * 2006-05-03 2008-01-10 Chimerix, Inc. Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates

Citations (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2087132A (en) * 1933-04-13 1937-07-13 Alba Pharmaceutical Company In Quaternary ammonium compounds
US2086585A (en) * 1933-04-13 1937-07-13 Alba Pharmaceutical Company In Quaternary ammonium compounds
US2108765A (en) * 1938-02-15 Preserving and disinfecting media
US2209383A (en) * 1938-03-05 1940-07-30 Rohm & Haas Process of waterproofing fabrics
US2439969A (en) * 1944-04-17 1948-04-20 Rhone Poulenc Sa Amino-dioxacyclopentanes
US2445393A (en) * 1944-03-08 1948-07-20 Rhone Poulenc Sa New amino-derivatives of dioxa-cyclopentane
US2513747A (en) * 1945-10-04 1950-07-04 Ciba Ltd Cyclic amino-acetals
US2606909A (en) * 1947-08-01 1952-08-12 Univ Michigan Basic dioxolanes
US2689790A (en) * 1951-09-26 1954-09-21 Monsanto Chemicals Nitrogenous compound herbicides
US2950253A (en) * 1953-07-29 1960-08-23 Bohme Fettchemie Gmbh Methods of washing textile fabrics
US3054678A (en) * 1958-04-16 1962-09-18 Michener Harold David Preservation process with quaternary ammonium compounds
US3694473A (en) * 1970-07-06 1972-09-26 Hansjorg E Eibl Higher alkano yl-propanediol-(1,3)-2 -trimethylammonium-ethyl phosphates
US4093714A (en) * 1974-03-15 1978-06-06 Icn Pharmaceuticals, Inc. 9β-D-Arabinofuranosylpurine nucleotides and method of use
US4096278A (en) * 1976-07-01 1978-06-20 Andre Queuille Organic derivatives of montmorillonite for treating lipid disturbances
US4119714A (en) * 1970-02-27 1978-10-10 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. Glycerin-alkylether-(1)-phosphoric acid-(3)-monocholine esters as enhancers of the natural resistance of the mammalian organism against non-carcinogenic pathogens
US4159988A (en) * 1974-08-06 1979-07-03 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Synthetic phospholipids, a process for their manufacture and their use
US4221732A (en) * 1978-05-12 1980-09-09 A. Nattermann & Cie. Gmbh Structural analogs of natural phospholipids
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4291024A (en) * 1978-04-10 1981-09-22 Turcotte Joseph G Cytotoxic liponucleotide analogs
US4329302A (en) * 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
US4426525A (en) * 1980-10-22 1984-01-17 Takeda Chemical Industries, Ltd. Certain phosphoric acid ester derivatives of 1,3-dioxy propane
US4444766A (en) * 1980-10-21 1984-04-24 Boehringer Mannheim Gmbh Sulfur-containing phospholipid compounds and therapeutic compositions
US4471113A (en) * 1982-02-03 1984-09-11 The United States Of America As Represented By The Department Of Energy Prodrugs based on phospholipid-nucleoside conjugates
US4540521A (en) * 1984-01-16 1985-09-10 National Distillers And Chemical Corporation Liquid quaternary ammonium antistatic compositions
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
US4608392A (en) * 1983-08-30 1986-08-26 Societe Anonyme Dite: L'oreal Method for producing a non greasy protective and emollient film on the skin
US4622392A (en) * 1984-06-21 1986-11-11 Health Research Inc. (Roswell Park Division) Thiophospholipid conjugates of antitumor agents
US4661509A (en) * 1982-09-28 1987-04-28 Gordon Arnold Z Methods for treating leukopenia
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4797479A (en) * 1985-04-15 1989-01-10 Toyo Jozo Kabushiki Kaisha Nucleoside-phospholipid conjugate
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4826823A (en) * 1985-02-05 1989-05-02 Warner-Lambert Company Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts
US4835263A (en) * 1983-01-27 1989-05-30 Centre National De La Recherche Scientifique Novel compounds containing an oligonucleotide sequence bonded to an intercalating agent, a process for their synthesis and their use
US4837023A (en) * 1985-12-04 1989-06-06 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Compositions containing hexadecylophosphocholine and alkylglycerols and uses thereof
US4841039A (en) * 1986-05-01 1989-06-20 Emory University 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
US4880782A (en) * 1986-11-21 1989-11-14 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Method of treating viral infections in humans and compositions therefor
US4921951A (en) * 1986-09-27 1990-05-01 Toyo Jozo Kabushiki Kaisha Nucleoside-phospholipid conjugate
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4997761A (en) * 1987-10-06 1991-03-05 Houston Biotechnology Incorporated Phosphatidyl treatment of viral disease
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5034394A (en) * 1988-06-27 1991-07-23 Burroughs Wellcome Co. Therapeutic nucleosides
US5138045A (en) * 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5221696A (en) * 1989-03-29 1993-06-22 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
US5496546A (en) * 1993-02-24 1996-03-05 Jui H. Wang Compositions and methods of application of reactive antiviral polyadenylic acid derivatives
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
US5614548A (en) * 1988-10-25 1997-03-25 Wake Forest University Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US5619917A (en) * 1993-12-06 1997-04-15 Riso Kagaku Corporation Stencil discharge apparatus
US5633388A (en) * 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5770584A (en) * 1993-06-10 1998-06-23 Wake Forest University Method of treating hepatitis virus infections
US5830905A (en) * 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5846964A (en) * 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
US5891874A (en) * 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5922757A (en) * 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
US5962757A (en) * 1994-12-14 1999-10-05 Shell Oil Company Dehydrogenation catalyst and process
US5985854A (en) * 1993-03-31 1999-11-16 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US6034134A (en) * 1997-06-30 2000-03-07 Merz + Co. Gmbh & Co. 1-Amino-alkylcyclohexane NMDA receptor antagonists
US6077837A (en) * 1995-06-07 2000-06-20 D-Pharm Ltd. Prodrugs with enhanced penetration into cells
US6243759B1 (en) * 1998-05-08 2001-06-05 International Business Machines Corporation Method and system for configuring dynamic interfaces
US6670341B1 (en) * 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US7141557B2 (en) * 1994-08-29 2006-11-28 Wake Forest University Lipid analogs for treating viral infections

Patent Citations (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2108765A (en) * 1938-02-15 Preserving and disinfecting media
US2087132A (en) * 1933-04-13 1937-07-13 Alba Pharmaceutical Company In Quaternary ammonium compounds
US2086585A (en) * 1933-04-13 1937-07-13 Alba Pharmaceutical Company In Quaternary ammonium compounds
US2209383A (en) * 1938-03-05 1940-07-30 Rohm & Haas Process of waterproofing fabrics
US2445393A (en) * 1944-03-08 1948-07-20 Rhone Poulenc Sa New amino-derivatives of dioxa-cyclopentane
US2439969A (en) * 1944-04-17 1948-04-20 Rhone Poulenc Sa Amino-dioxacyclopentanes
US2513747A (en) * 1945-10-04 1950-07-04 Ciba Ltd Cyclic amino-acetals
US2606909A (en) * 1947-08-01 1952-08-12 Univ Michigan Basic dioxolanes
US2689790A (en) * 1951-09-26 1954-09-21 Monsanto Chemicals Nitrogenous compound herbicides
US2950253A (en) * 1953-07-29 1960-08-23 Bohme Fettchemie Gmbh Methods of washing textile fabrics
US3054678A (en) * 1958-04-16 1962-09-18 Michener Harold David Preservation process with quaternary ammonium compounds
US4119714A (en) * 1970-02-27 1978-10-10 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. Glycerin-alkylether-(1)-phosphoric acid-(3)-monocholine esters as enhancers of the natural resistance of the mammalian organism against non-carcinogenic pathogens
US3694473A (en) * 1970-07-06 1972-09-26 Hansjorg E Eibl Higher alkano yl-propanediol-(1,3)-2 -trimethylammonium-ethyl phosphates
US4093714A (en) * 1974-03-15 1978-06-06 Icn Pharmaceuticals, Inc. 9β-D-Arabinofuranosylpurine nucleotides and method of use
US4159988A (en) * 1974-08-06 1979-07-03 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Synthetic phospholipids, a process for their manufacture and their use
US4096278A (en) * 1976-07-01 1978-06-20 Andre Queuille Organic derivatives of montmorillonite for treating lipid disturbances
US4291024A (en) * 1978-04-10 1981-09-22 Turcotte Joseph G Cytotoxic liponucleotide analogs
US4221732A (en) * 1978-05-12 1980-09-09 A. Nattermann & Cie. Gmbh Structural analogs of natural phospholipids
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4329302A (en) * 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
US4444766A (en) * 1980-10-21 1984-04-24 Boehringer Mannheim Gmbh Sulfur-containing phospholipid compounds and therapeutic compositions
US4426525A (en) * 1980-10-22 1984-01-17 Takeda Chemical Industries, Ltd. Certain phosphoric acid ester derivatives of 1,3-dioxy propane
US4471113A (en) * 1982-02-03 1984-09-11 The United States Of America As Represented By The Department Of Energy Prodrugs based on phospholipid-nucleoside conjugates
US4661509A (en) * 1982-09-28 1987-04-28 Gordon Arnold Z Methods for treating leukopenia
US4835263A (en) * 1983-01-27 1989-05-30 Centre National De La Recherche Scientifique Novel compounds containing an oligonucleotide sequence bonded to an intercalating agent, a process for their synthesis and their use
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
US4608392A (en) * 1983-08-30 1986-08-26 Societe Anonyme Dite: L'oreal Method for producing a non greasy protective and emollient film on the skin
US4540521A (en) * 1984-01-16 1985-09-10 National Distillers And Chemical Corporation Liquid quaternary ammonium antistatic compositions
US4622392A (en) * 1984-06-21 1986-11-11 Health Research Inc. (Roswell Park Division) Thiophospholipid conjugates of antitumor agents
US4826823A (en) * 1985-02-05 1989-05-02 Warner-Lambert Company Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4797479A (en) * 1985-04-15 1989-01-10 Toyo Jozo Kabushiki Kaisha Nucleoside-phospholipid conjugate
US4837023A (en) * 1985-12-04 1989-06-06 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Compositions containing hexadecylophosphocholine and alkylglycerols and uses thereof
US4841039A (en) * 1986-05-01 1989-06-20 Emory University 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4921951A (en) * 1986-09-27 1990-05-01 Toyo Jozo Kabushiki Kaisha Nucleoside-phospholipid conjugate
US4880782A (en) * 1986-11-21 1989-11-14 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Method of treating viral infections in humans and compositions therefor
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4997761A (en) * 1987-10-06 1991-03-05 Houston Biotechnology Incorporated Phosphatidyl treatment of viral disease
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5034394A (en) * 1988-06-27 1991-07-23 Burroughs Wellcome Co. Therapeutic nucleosides
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5614548A (en) * 1988-10-25 1997-03-25 Wake Forest University Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US5221696A (en) * 1989-03-29 1993-06-22 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5138045A (en) * 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
US5496546A (en) * 1993-02-24 1996-03-05 Jui H. Wang Compositions and methods of application of reactive antiviral polyadenylic acid derivatives
US6136796A (en) * 1993-03-13 2000-10-24 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US5985854A (en) * 1993-03-31 1999-11-16 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US6030960A (en) * 1993-06-10 2000-02-29 Wake Forest University Method of treating hepatitis virus infections
US5770584A (en) * 1993-06-10 1998-06-23 Wake Forest University Method of treating hepatitis virus infections
US5846964A (en) * 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
US5619917A (en) * 1993-12-06 1997-04-15 Riso Kagaku Corporation Stencil discharge apparatus
US7141557B2 (en) * 1994-08-29 2006-11-28 Wake Forest University Lipid analogs for treating viral infections
US5962757A (en) * 1994-12-14 1999-10-05 Shell Oil Company Dehydrogenation catalyst and process
US6077837A (en) * 1995-06-07 2000-06-20 D-Pharm Ltd. Prodrugs with enhanced penetration into cells
US6166089A (en) * 1995-06-07 2000-12-26 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US5633388A (en) * 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5830905A (en) * 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5891874A (en) * 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5922757A (en) * 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
US6034134A (en) * 1997-06-30 2000-03-07 Merz + Co. Gmbh & Co. 1-Amino-alkylcyclohexane NMDA receptor antagonists
US6243759B1 (en) * 1998-05-08 2001-06-05 International Business Machines Corporation Method and system for configuring dynamic interfaces
US6670341B1 (en) * 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080009462A1 (en) * 2006-05-03 2008-01-10 Chimerix, Inc. Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates
US7749983B2 (en) 2006-05-03 2010-07-06 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
US7994143B2 (en) 2006-05-03 2011-08-09 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates

Also Published As

Publication number Publication date
WO2005099719A3 (en) 2007-03-22
WO2005099719A2 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
US20100273740A1 (en) Phospholipids for the Treatment of Infection by Togaviruses, Herpes Viruses and Coronaviruses
US8114994B2 (en) 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation
CN104640540B (en) Enhanced anti-influenza agents coupled with anti-inflammatory activity
KR100304246B1 (en) Enantiomerically pure β-D-dioxolane nucleoside with selective anti-hepatitis B virus activity
TWI678369B (en) Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidines useful for treating respiratory syncitial virus infections
US20140212382A1 (en) Purine monophosphate prodrugs for treatment of viral infections
US20240166680A1 (en) Nucleoside analog and use thereof
KR102233826B1 (en) Thiazolide compounds for treating viral infections
CN116322759A (en) Phospholipid compounds and their uses
PL141198B1 (en) Process for preparing derivatives of purine
KR20020097384A (en) A Medicament which is Effective for a Virus Having a Resistance Mutation against a Known Medicament
US20140249165A1 (en) Purine derivatives for treatment of cystic diseases
US9714259B2 (en) Compositions and methods for improving glucose uptake
US20050187191A1 (en) Methods and compositions for the treatment of respiratory syncytial virus
CN111670189A (en) Cycloalkyl-substituted pyrazolopyrimidines having activity on RSV
EP2659891B1 (en) Drug with activity against the herpes virus family
RU2663803C2 (en) Treatment of helicobacter pylori infections with use of mtan inhibitors
CN112999210B (en) Application of mitoxantrone and its structural analogs in treating pseudorabies virus
ES2342558T3 (en) AGENT FOR PREVENTION / TREATMENT OF A DISEASE CAUSED BY A HERPESVIRUS RESISTANT TO ACYCLOVIR.
WO2024129985A2 (en) Antiviral compounds, compositions, and uses thereof
US20240041854A1 (en) Cold medicine and antiviral medicine
WO2022013478A1 (en) Diagnostic method and compounds for the treatment of infections caused by a pathogen
CN102112461B (en) Novel diaryl hepatonoid compound and use thereof
HK1214267B (en) Compositions and methods for improving glucose uptake
TH22934A (en) L-monovaline ester obtained from 2- (2-amino-1,6-dihydro-6-oxo-furin-9-il) methoxi-1. , 3- propanediol And its salts that accept the drug with better absorption

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KUCERA, LOUIS S.;FLEMING, RONALD A.;HESS, JAN V.;AND OTHERS;REEL/FRAME:015575/0207;SIGNING DATES FROM 20040701 TO 20040712

Owner name: KUCERA PHARMACEUTICAL COMPANY, NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KUCERA, LOUIS S.;FLEMING, RONALD A.;HESS, JAN V.;AND OTHERS;REEL/FRAME:015575/0207;SIGNING DATES FROM 20040701 TO 20040712

Owner name: WAKE FOREST UNIVERSITY HEALTH SCIENCES, NORTH CARO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KUCERA, LOUIS S.;FLEMING, RONALD A.;HESS, JAN V.;AND OTHERS;REEL/FRAME:015575/0207;SIGNING DATES FROM 20040701 TO 20040712

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND

Free format text: LICENSE;ASSIGNOR:WAKE FOREST UNIVERSITY;REEL/FRAME:069387/0730

Effective date: 20240524